PHAXIAM Therapeutics (PHXM) 6-K 26 Sep 23 2023 Q2 I.Certification of the Person Responsible for the Half-year Financial Report Financial data

COVER

COVER	6 Months Ended
	Jun. 30, 2023
Cover [Abstract]
Document Type	6-K
Entity Registrant Name	PHAXIAM Therapeutics S.A.
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001624422
Current Fiscal Year End Date	--12-31

UNAUDITED INTERIM CONDENSED CON

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) € in Thousands, $ in Thousands		6 Months Ended
		Jun. 30, 2023 EUR (€) € / shares	Jun. 30, 2022 EUR (€) € / shares
Profit or loss [abstract]
Revenues		€ 0	€ 0
Other income		278	25,304
Operating income		278	25,304
Research and development		(3,431)	(17,300)
General and administrative		(9,245)	(7,911)
Operating expenses		(12,676)	(25,211)
Operating loss		(12,398)	93
Financial income		331	3,370
Financial expenses		(342)	(750)
Financial income (loss)		(11)	2,620
Income tax		208	(3,737)
Net loss		€ (12,201)	€ (1,024)
Basic loss per share (€/share) | € / shares	[1]	€ (3.71)	€ (0.33)
Diluted loss per share (€/share) | € / shares	[1]	€ (3.71)	€ (0.33)
[1]Following PHAXIAM reverse share split by exchange of ten existing share for one new share on September 18th 2023, the Basic /Diluted loss per share has been restated retrospectively for all periods presented.

UNAUDITED INTERIM CONDENSED C_2

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT COMPREHENSIVE OF INCOME (LOSS) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statement of comprehensive income [abstract]
Net loss	€ (12,201)	€ (1,024)
Elements that may be reclassified subsequently to income (loss)
Currency translation adjustment	(153)	66
Elements that may not be reclassified subsequently to income (loss)
Remeasurement of defined benefit liabilities	32	224
Tax effect	0	0
Other comprehensive income (loss)	(121)	290
Comprehensive income (loss)	€ (12,322)	€ (734)

UNAUDITED INTERIM CONDENSED C_3

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Non-current assets
Intangible assets other than goodwill	€ 17,101	€ 5
Goodwill	13,503	0
Property, plant and equipment	857	393
Right of use	2,943	2,584
Other non-current assets	205	195
Total non-current assets	34,609	3,177
Current assets
Trade and other receivables	245	76
Other current assets	5,488	3,769
Cash and cash equivalents	25,189	38,789
Total current assets	30,922	42,634
TOTAL ASSETS	65,531	45,811
Shareholders’ equity
Share capital	6,075	3,102
Premiums related to share capital	49,671	48,975
Reserves	(8,162)	(29,765)
Translation reserve	1,249	1,402
Net loss for the period	(12,201)	(228)
Total shareholders’ equity	36,632	23,487
Non-current liabilities
Provisions - non-current portion	397	419
Financial liabilities – non-current portion	8,552	7,547
Non-current derivative financial liabilities	0	0
Lease liabilities - non-current portion	2,559	2,680
Deferred tax	0	0
Total Non-current liabilities	11,508	10,646
Current liabilities
Provisions - current portion	208	314
Financial liabilities – current portion	3,201	2,565
Derivative liabilities - current portion	0	0
Lease liabilities - current portion	828	775
Trade and other payables	9,120	5,115
Other current liabilities	4,033	2,909
Total current liabilities	17,390	11,678
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	€ 65,531	€ 45,811

UNAUDITED INTERIM CONDENSED C_4

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - EUR (€) € in Thousands		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Cash flows used in operating activities
Net loss		€ (12,201)	€ (1,024)
Reconciliation of net loss and the cash used for operating activities
Gain or loss on exchange		102	(2,743)
Amortization and depreciation		211	4,289
Provision		(144)	1,807
Extinguishment of conditional advance		0	0
Change in fair value of derivative liabilities		0	0
Expenses related to share-based payments		390	326
(Gain) or loss on disposal of property plant and equipment	[1]	0	(24,351)
Interest expense (income)		(68)	242
Income tax expense (income)		(208)	3,737
Operating cash flow before change in working capital		(11,918)	(17,717)
(Increase) decrease in inventories		0	0
(Increase) decrease in trade and other receivables		76	(278)
(Increase) decrease in other current assets		(359)	720
Increase (decrease) in trade and other payables		694	(2,351)
Increase (decrease) in other current liabilities		(90)	(1,065)
Change in working capital		320	(2,974)
Income tax paid		(297)	(3)
Net cash flow used in operating activities		(11,895)	(20,694)
Cash flows from investing activities
Cash acquired from business combination	[2]	10	0
Acquisition of property, plant and equipment		(53)	(7)
Acquisition of intangible assets		0	0
Increase in non-current & current financial assets		0	(5)
Disposal of property, plant and equipment		0	37,630
Decrease in non-current & current financial assets		233	329
Net cash flow from investing activities		190	37,947
Cash flows from (used in) financing activities
Capital increases, net of transaction costs		0	0
Proceeds from borrowings, net of transaction costs		0	3,088
Repayment of borrowings		(1,282)	0
Repayment of lease liability (IFRS 16)		(414)	(907)
Interests received (paid)			(193)
Interests received (paid)		77
Net cash flow from (used in) financing activities		(1,619)	1,988
Exchange rate effect on cash in foreign currency		(276)	399
Increase (Decrease) in cash and cash equivalents		(13,600)	19,640
Net cash and cash equivalents at the beginning of the period		38,789	33,699
Net cash and cash equivalents at the closing of the period		25,189	53,339
Cash paid for interest		€ (77)	€ 193
[1]including €24,350 thousand related to Catalent sale of Princeton manufacturing facility (see Note 3.1)[2]includes the cash acquired from PHERECYDES Pharma for €10 thousand.

UNAUDITED INTERIM CONDENSED C_5

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - EUR (€) € in Thousands		Total	Share capital	Premiums related to the share capital	Reserves	Translation reserve	Net income (loss)
Beginning balance at Dec. 31, 2021		€ 22,845	€ 3,102	€ 97,618	€ (25,293)	€ 1,215	€ (53,797)
Net loss		(1,024)					(1,024)
Other comprehensive income		290			224	66
Comprehensive income (loss)		(734)			224	66	(1,024)
Allocation of prior period loss				(48,643)	(5,154)		53,797
Share-based payment		326			326
Ending balance at Jun. 30, 2022		22,436	3,102	48,975	(29,897)	1,281	(1,024)
Beginning balance at Dec. 31, 2022		23,487	3,102	48,975	(29,765)	1,402	(228)
Net loss		(12,201)					(12,201)
Other comprehensive income		(121)			32	(153)
Comprehensive income (loss)		(12,322)			32	(153)	(12,201)
Allocation of prior period loss	[1]			(21,408)	21,180		228
Issue of ordinary shares	[2]	25,077	2,973	22,104
Share-based payment		391			391
Ending balance at Jun. 30, 2023		€ 36,632	€ 6,075	€ 49,671	€ (8,162)	€ 1,249	€ (12,201)
[1]For each of the years presented the standalone net loss of Erytech Pharma SA has been allocated to the Premiums pursuant to a shareholder meeting decision[2]Refer to footnote 4.1.2

UNAUDITED INTERIM CONDENSED C_6

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) € in Thousands, $ in Millions		1 Months Ended		6 Months Ended
		Apr. 30, 2022 EUR (€)	Apr. 30, 2022 USD ($)	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 EUR (€)
Disclosure of detailed information about property, plant and equipment [line items]
Cash acquired from business combination	[1]			€ 10	€ 0
Cell Therapy Manufacturing Facility
Disclosure of detailed information about property, plant and equipment [line items]
Gains on disposals of property, plant and equipment		€ 24,300	$ 26.6
[1]includes the cash acquired from PHERECYDES Pharma for €10 thousand.

DESCRIPTION OF THE BUSINESS

DESCRIPTION OF THE BUSINESS	6 Months Ended
	Jun. 30, 2023
Disclosure Of Description Of Business [Abstract]
DESCRIPTION OF THE BUSINESS	DESCRIPTION OF THE BUSINESS PHAXIAM Therapeutics (“ PHAXIAM ,” and together with its subsidiary the “ Company ”, previously ERYTECH Pharma S.A.) is incorporated in Lyon, France, and was founded in 2004 to develop and market innovative red blood cell-based therapeutics for cancer and orphan diseases. Since the merger with Pherecydes on June 23, 2023, PHAXIAM Therapeutics focuses on becoming a global leader in the treatment of bacterial infections using bacteriophages (or phages), natural viruses capable of fighting antibiotic-resistant bacteria. The Company completed its initial public offering on Euronext Paris in May 2013, raising €17.7 million, and on the Nasdaq Global Select Market in November 2017, raising €124.0 million ($144.0 million on a gross basis before deducting offering expenses). The Company has incurred losses and negative cash flows from operating activities since its inception and had shareholders’ equity of €36,632 thousand as of June 30, 2023 as a result of several financing rounds, including an initial public offering, as well as the capital increase in connection with the Pherecydes transaction. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates in development. The Company’s future operations are highly dependent on a combination of factors, including: (i) the success of the research and development of the newly formed "Combined Company" following the recent merger with Pherecydes; (ii) regulatory approval and market acceptance of the PHAXIAM proposed future products; (iii) the timely and successful completion of additional financing; and (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through the issuance of new debt or equity instruments. The situation on the financial markets and uncertainty in the research and development results may impair the ability of the Company to raise capital when needed or on attractive terms. The accompanying unaudited interim condensed consolidated financial statements and related notes (the “ Unaudited Interim Condensed Consolidated Financial Statements ”) present the operations of PHAXIAM Therapeutics and its subsidiary, ERYTECH Pharma, Inc. Registered office of PHAXIAM Therapeutics: 60 avenue Rockefeller, 69008, Lyon, France. Major events of the first half of 2023 Business February 2023: On February 15, 2023, ERYTECH announced the strategic combination with Pherecydes, a biotechnology company specializing in precision phage therapy to treat resistance and/or complicated bacterial infections, with the intent of building a global leader in phage therapy. March 2023: On March 20, 2023, ERYTECH's Work Council ( Comité Social et Economique ) issued a positive opinion on the proposed merger with PHERECYDES, in accordance with applicable laws and regulations. April 2023: ERYTECH Pharma received approval from The Nasdaq Stock Market LLC on April 12, 2023, to transfer the listing of its American Depositary Shares representing ordinary shares of the Company ("ADSs") from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer became effective at the opening of business on April 14, 2023. The ERYTECH shares continued to trade under the symbol "ERYP" and the trading of its ADSs was unaffected by the transfer. On April 17, 2023, Akkadian Partners, an entity domiciled in Luxembourg and acting on behalf of the Akkadian Partners Fund, declared that on April 13, 2023, they crossed the threshold of 5% of the share capital of ERYTECH Pharma and held 5.06% of the share capital and 4.83% of the voting rights of the company. May 2023: On May 1, 2023, Akkadian Partners informed the Board of ERYTECH that they intended to oppose the project of merging with PHERECYDES and take de facto control of ERYTECH with a view to pursue alternative acquisition projects with ERYTECH's cash. Following a review and assessment of the acquisition project ideas mentioned by Akkadian, ERYTECH Management and Board, with the assistance of external financial and legal advisors, determined that the ideas proposed were not in the best interest of ERYTECH and its stakeholders. On May 15, 2023, ERYTECH and PHERECYDES entered into a merger agreement, pursuant to which PHERECYDES would be merged into ERYTECH and PHERECYDES shareholders would receive 15 new ERYTECH shares for every 4 PHERECYDES shares that they owned. A contribution by Elaia Pertners, GoCapital, and a pool of PHERECYDES shareholders represented by Mr. Guy Rigaud, of 827,132 PHERECYDES shares was made to ERYTECH in consideration of 3,101,745 newly issued ERYTECH shares. June 2023: On June 5, 2023, ERYTECH Pharma announced that Akkadian Partners had initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23, 2023. On June 14, 2023, the Lyon Commercial Court rejected Akkadian's request to postpone the vote on the merger with PHERECYDES Pharma. On June 20, 2023, ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit. Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request to postpone the General Meeting's vote on the proposed merger Akkadian Partners is requesting the cancellation of the capital increase of May 15, 2023. This capital increase was carried out in accordance with the delegation of authority granted by the 2022 extraordinary general meeting of ERYTECH shareholders under resolution 29 and on the basis of reports issued by Finexsi, acting as a contribution appraiser in accordance with Articles L. 225-174, R. 22 10-7 and R. 225-136 pf the French Commercial Code as well as AMF recommendation no. 2020-06. On June 23, 2023, the merger with PHERECYDES was approved by the ERYTECH Pharma shareholders at the Combined General Meeting. Also approved was the change to ERYTECH's corporate name to PHAXIAM Therapeutics. On June 28, 2023 PHAXIAM Therapeutics announced the new mnemonic code for its shares on Euronext and Nasdaq to have changed from ERYP to PHXM, effective June 29, 2023. Major events of the first half of 2022 Business February 2022: Impact of the Conflict in Ukraine on Our Business Beginning on February 24, 2022, Russia significantly intensified its military operations in Ukraine. We are closely monitoring developments in the current context and will take appropriate measures as necessary. The war in Ukraine did not impact our financial results for the period ended on December 31, 2022. Our business does not conduct any trial in Ukraine, Russia or Belarus and does not have any asset or vendors located in these regions. April 2022: • Sale of ERYTECH’s U.S. cell therapy manufacturing facility to Catalent Under the terms of an asset purchase agreement between the Group ERYTECH and Catalent (the “APA”), Catalent agreed to acquire ERYTECH’s state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total gross consideration of $44.5 million (€40.7 million) paid at closing. Catalent has extended offers of employment to approximately 40 people employed by Erytech at the Princeton facility. The net profit on the sale of the property, plant and equipments, lease contract, after transaction cost ( $3.3 million, €3.0 million) and before tax amounts to 26.6 million dollars (€24.3 million euros) and was recorded as other income in the consolidated statement of income (loss) . • New vesiculation technology The company presented its red blood cell vesiculation technology at the 24th Meeting of the European Red Cell Society (ERCS) in April 2022. May 2022: • The NOPHO trial evaluated the safety and pharmacological profile of eryaspase in acute lymphoblastic leukemia (ALL) patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy. In December 2020, positive trial results were presented at the 2020 American Society of Hematology annual meeting. See section 2.2. – activities of the Group and 2.5 - events after the reporting period for further information. • Following the Catalent transaction, the company continues to evaluate other strategic options for leveraging its ERYCAPS® platform with complementary assets and/or a broader corporate transaction. • On May 25, 2022, the management of Erytech Pharma (France) informed the employees of the start of a collective redundancy procedure, a job protection plan, involving the cuts of 52 positions out of 109. The consultation phase of the CSE has ended on July 31, 2022. All terminations took place during the fourth quarter 2022.

ACCOUNTING RULES AND METHODS

ACCOUNTING RULES AND METHODS	6 Months Ended
	Jun. 30, 2023
Accounting Rules And Methods [Abstract]
ACCOUNTING RULES AND METHODS	ACCOUNTING RULES AND METHODSBasis of preparation The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with the underlying assumption of going concern assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern. The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the products developed, therefore involving a multi-year research and development phase. The Company has historically financed its growth by strengthening its equity in the form of capital increases and issuance of convertible notes. At the date the Board of Directors authorized the unaudited interim condensed consolidated financial statements the Company has the necessary resources to fund its operations into the second quarter 2024 considering: • Cash and cash equivalents held by the Company amounted to €25.2 million as of June 30, 2023. They are composed of cash and term deposits readily available without penalty; • The cash consumption forecast for the next 12 months after the closing date. Accordingly, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern. Therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. The Company plans to seek additional financing to extend its cash flow horizon and is currently evaluating various financing sources among which are the issuance of equity instruments and/or new debt or partnership agreements to continue to fund the operations of the Company beyond the second quarter of 2024. The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with the historical cost principle with the exception of certain categories of assets and liabilities measured at fair value in accordance with IFRS. All amounts are expressed in thousands of euros, unless stated otherwise. The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with IAS 34, the standard of the International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standard Board (“ IASB ”) applicable to interim financial statements and were authorized for issuance by the Board of Directors of the Company on September 21, 2023. Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the Unaudited Interim Condensed Consolidated Financial Statements of the Company are also prepared in accordance with IAS 34, as adopted by the European Union (EU). As condensed consolidated financial statements, they do not include all information that would be required by the full IFRS standards. They must be read in conjunction with the consolidated financial statements for the year ended December 31, 2022. The standards applied in the preparation of the Unaudited Interim Condensed Consolidated Financial Statements are the same as those applied to prepare the financial statements as of December 31, 2022, except as described below. As of June 30, 2023, all IFRS that the IASB had published and that are mandatory are the same as those endorsed by the EU and mandatory in the EU. As a result, the Unaudited Interim Condensed Consolidated Financial Statements comply with International Financial Reporting Standards as published by the IASB and as adopted by the EU. IFRS include International Financial Reporting Standards (“ IFRS ”), International Accounting Standards (“ IAS ”), as well as the interpretations issued by the Standing Interpretations Committee (“ SIC ”), and the International Financial Reporting Interpretations Committee (“ IFRS IC ”). The new applicable standards, amendments and interpretations since January 1, 2023 have had no significant impact on the Company’s consolidated financial statements. Recently issued accounting pronouncements that may be relevant to the Company’s operations are as follows: • Amendments to IAS 1 - Classification of liabilities as current or non-current ; Disclosure of Accounting Policies, effective on January 1, 2024; • Amendments to IAS 8 - Definition of Accounting Estima tes, effective on January 1, 2023; • Amendment to IAS12 - Deferred Tax related to Assets and Liabilities arising from a Single Transaction, , effective on January 1, 2023; The Company does not expect any significant impact resulting from the adoption of these standards. In accordance with IFRS 10 Consolidated Financial Statements (“ IFRS 10 ”), an entity is consolidated when it is controlled by the Company. The Company controls an entity when it is exposed or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. All intercompany balances, transactions and dividends are eliminated in full. The Company has one subsidiary for which no non-controlling interest is recognized. Date of Incorporation Percent of Ownership Interest Accounting Method ERYTECH Pharma, Inc. April 2014 100% Consolidated Functional Currency and Translation of Financial Statements into Presentation Currency The Unaudited Interim Condensed Consolidated Financial Statements are presented in euros, which is also the functional currency of the parent company, PHAXIAM Therapeutics (the “ Parent Company ”). The statement of financial position of the consolidated entity having a functional currency different from the euro are translated into euros at the closing exchange rate (spot exchange rate at the statement of financial position date) and the statement of income (loss), statement of comprehensive income (loss) and statement of cash flow of such consolidated entity are translated at the average exchange rate for the period, except if exchange rates or the volume and size of transactions fluctuate significantly. The resulting translation adjustment is included in other comprehensive income (loss) as a cumulative translation adjustment. Exchange rate (USD per EUR) 06/30/2022 12/31/2022 06/30/2023 Weighted average rate 1.0940 1.0539 1.0811 Closing rate 1.0387 1.0666 1.0866 Conversion of Foreign Currency Transactions Foreign currency transactions are converted to functional currency at the exchange rate applicable on the transaction date. At the closing date, foreign currency monetary assets and liabilities are converted at the exchange rate prevailing on that date. The resulting exchange gains or losses are recorded in the consolidated statement of income (loss) in “Financial income (loss)”. Preparation of the consolidated financial statements in accordance with the rules prescribed by the IFRS requires the use of estimates and the formulation of assumptions having an impact on the financial statements. These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The Company has not identified any environmental risks that would require significant new estimates or judgments. The use of estimates and judgment relate primarily to the measurement of: • fair value of in progress research and developments assets identified in business combination (see Note 4.1.1 and 4.1.2) • the share-based payments in accordance with IFRS 2 (see note 3.3.3) In accordance with IFRS 8 Operating Segments ( "IFRS 8" ) , reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Chief Executive Officer) to allocate resources and to assess performance. Information per business segment The Company operates in a single operating segment: the conducting of research and development of extended phage therapies to target antimicrobial resistant pathogenic bacteria in order to market the phage therapies in the future. Information per geographical segment Income from external customers (amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) France 0 0 United States 54 7 Total 54 7 On June 27, 2023 and July 28, 2023 , Akkadian Partners initiated two other legal proceedings to contest the votes of certain Shareholder's of ERYTECH and request the cancellation of the merger as voted in the combined General Meeting. On July 27, 2023, PHAXIAM Therapeutics announced a reverse share split of its shares by the exchange of ten (10) existing shares with a par value of ten-euro cents (€0.10) for one (1) new share with a par value of one euro (€1). The reverse share split will have no impact on the Company's share capital and will result in the division of the number of shares outstanding by ten (10). The reverse share split ended on September 18, 2023 with sixty million seven hundred and fifty-one thousand and fifty-four (60,751,054) existing shares exchanged for six million seventy five thousand one hundred and five (6,075,105) new shares issued as a result of the reverse share split. On September 19, 2023, PHAXIAM Therapeutics announced that it extended its phage portfolio to Klebsiella pneumoniae , a new resistant and aggressive bacterial target. PHAXIAM's anti- Klensiella pneumoniae phages will enter preclinical development to assess their efficacy in lung, blood and urinary tract infections, in addition to the three major targets already developed ( S. aureus, P. aeruginosa, and E. coli ).

NOTES RELATED_TO THE UNAUDITED

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS)	6 Months Ended
	Jun. 30, 2023
Disclosure Of Detailed Information Of Operating Income Loss [Abstract]
NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS)	NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS)Operating income (amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) Research Tax Credit 860 243 Subsidies 40 28 Income from licenses or other contracts 54 7 Net gain on disposal of tangible assets 24,351 — Total 25,304 278 The reduction in the research tax credit is related to the end of previous clinical trials. The net gain from the disposal of fixed assets is related to the sale of the Princeton plant to Catalent and breaks down as follows : – Proceeds from the sale of €40,676 thousand ($44,500 thousand); – The net book value of tangible fixed assets of €15,673 thousand ($17,146 thousand); – The net book value of intangible fixed assets of €4 thousand ($4 thousand) – The net book value of the rights of use for €3,022 thousand ($3,307 thousand); – The cancellation of the lease obligation for €5,419 thousand ($5,928 thousand); – Transaction costs of €3,046 thousand ($3,333 thousand) Amounts in the prior period have been reclassified to conform to the current period presentation. Specifically, the regulatory activities are disclosed separately in this table but were included among clinical studies in the previously filed unaudited interim condensed financial statements of the 6 months ended June 30, 2022). For the six months ended June 30, 2022 (amounts in thousands of euros) R&D Regulatory Clinical studies Total Consumables 0 450 450 IT costs and maintenance 66 765 831 Services, subcontracting and fees 237 723 3,128 4,088 Personnel expenses 785 467 7,110 8,362 Depreciation, amortization & impairment 178 3,443 3,621 Other 7 (59) (52) Total 1,273 1,190 14,837 17,300 For the six months ended June 30, 2023 (amounts in thousands of euros) R&D Regulatory Clinical studies Total Consumables 128 0 101 229 IT costs and maintenance (14) 2 113 101 Services, subcontracting and fees 210 (144) 228 294 Personnel expenses 911 348 1,381 2,640 Depreciation, amortization & impairment 209 0 (58) 151 Other 0 0 16 16 Total 1,444 206 1,781 3,431 The €13.9 million significant decrease in research and development expenses between 2023 and 2022 can mainly be explained by: – a decrease of €3.8 million, of services and subcontracting expenses – a decrease of €5.7 million of personnel expenses, with the transfer to Catalent of Princeton manufacturing facility employees in April 2022 and the restructuring plan in Lyon completed in the fourth quarter 2022. The average number of full-time employees allocated to our research and development workforce decreased from 117 in the first half of 2022 to 27 in the first half of 2023. The personnel expense in 2022 includes a Lyon (France) restructuring charge of €1.7 million. – a net decrease in depreciation and amortization expenses of €3.5 million in 2023, mainly related to: – the disposal of our Princeton Manufacturing facility sold to Catalent in April 2022 – an impairment charge of €2.1 million in 2022 for the facilities, fixtures, equipment and rights of use of the Adenine production unit in France. (amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) Consumables 57 47 IT Costs and maintenance 175 442 Services, subcontracting and fees 3,446 5,664 Personnel expenses 3,288 2,957 Depreciation and amortization 669 (110) Other 277 246 Total 7,911 9,245 The €1.33 million increase of general and administrative expenses between 2022 and 2023 is explained mostly by the €3.41 million in merger costs, partially offset by personnel expenses reductions and a reduction to service and subcontracting fees. G&A personnel expenses decreased by €0.3 million in 2023, with the combined effects of employees resignations and a restructuring plan in Lyon completed in the last quarter of 2022. The average number of full-time employees allocated to our G&A workforce decreased from 32 in the 6 months ended June 30, 2022 to 18 in the 6 months ended June 30, 2023. The personnel expense in 2022 includes a Lyon (France) restructuring charge of €0.2 million. Services, subcontracting and fees increased by €2.2 million from 2022 to 2023 due to €3.41 million in merger costs, partially offset by a reduction of D&O insurance costs, recruiting, and legal and audit fees. For the six months ended June 30, 2022 (amounts in thousands of euros) R&D Regulatory Clinical studies Total Wages and salaries 533 381 4,237 5,151 Share-based payments (employees and executive management) 17 (27) (10) Social security expenses 235 86 1,209 1,530 Restructuring charge 1,691 1,691 Total personnel expenses 785 467 7,110 8,362 For the six months ended June 30, 2023 (amounts in thousands of euros) R&D Regulatory Clinical studies Total Wages and salaries 603 287 1,047 1,937 Share-based payments (employees and executives) 33 0 114 147 Social security expenses 275 61 220 556 Total personnel expenses 911 348 1,381 2,640 The weighted average full-time employees (FTE) was 117 during the first half of 2022 and 27 during the first half of 2023. (amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) Wages and salaries 2,051 2,082 Share-based payments (employees and executive management) 304 230 Social security expenses 766 645 Restructuring charge 167 Total personnel expenses 3,288 2,957 The weighted average full-time employees (FTE) was 32 during the first half of 2022 an d 18 during the first half of 2023. Stock options (“SO”) plan No new plans were created during the first half of 2023, and no new grants were issued under plans from the prior year. Replacement awards: In connection with the acquisition of Pherecydes Pharma S.A., the Company exchanged equity-settled share-based payment awards held by employees of Pherecydes Pharma for the following equity-settled share-based payment awards of the Company (see note 4.1.2). - Founder Subscription Warrants (“BSPCE”) plan Figures are shown after the reverse stock split. Plan BSPCE 2019-1 BSPCE 2019-2 BSPCE 2019-4 BSPCE 2021-2 BSPCE 2021-3 BSPCE 2021-4 Number of options 3,691 7,500 263 7,500 6,328 62,325 Exercise price €1.09 €0.92 €1.09 €1.60 €2.19 €1.89 Underlying price €0.00 €0.47 €0.46 €0.40 €0.34 (Tranche 3) €0.35 (Tranche 4) €0.37 Expected dividends — % — % — % — % — % — % Volatility 87.14% - 92.92% 87.01% - 98.86% 84.03% - 89.19% 82.99% - 88.93% 79.89% - 88.22% 80.52% - 88.06% Risk-free rate 3.0108% - 3.2655% 2.9750% - 3.2290% 2.8787% -3.1274% 2.8033% - 3.1269% 2.8517% - 3.0093% 2.8625% - 2.9676% Fair value of the plan (in K€) 0.00 3.53 0.12 3.00 4.37 23.06 - Free shares (“AGA”) plan Figures are shown after the reverse stock split. Erytech Number of shares 16,460 Plan AGA 2022 Underlying price €0.82 Expected dividends — % Maturity 1 year - 3 years Fair value of plan (in K€) 135 Breakdown of expenses per financial year Plan name Amount in P&L in euros thousands as of June 30, 2022 of which employees of which executive officers and executive committee of which board members AGA 202 31 171 — BSA — — — — SO 124 53 71 — Total 326 84 242 — Plan name Amount in P&L in euros thousands as of June 30, 2023 of which employees of which executive officers and executive committee of which board members AGA 66 — 66 — BSPCE 435 222 104 109 SO (110) (123) 13 — Total 391 99 183 109 As of June 30, 2023, and after taking into account the effect of the reverse share split (see Note 2.9), the outstanding equity instruments could lead to the issuance of 396,318 potential shares. (amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) Income from short term deposits 6 171 Change in fair value of derivative liabilities — — Foreign exchange gains 3,348 137 Other financial income 16 23 Financial income 3,370 331 Amortized cost of convertible notes (22) — Financial expenses on lease liability (108) (25) Interest expense related to borrowings (140) (78) Foreign exchange loss (480) (239) Other financial expenses — — Financial expenses (750) (342) Financial income (loss) 2,620 (11) In June 2022 an estimate of the Income tax expense related to the Princeton facility sale was recorded for $4,086 thousand (€3,737 thousand). After completion of a tax analysis to determine the extent of prior year federal and state tax losses which could be carried forward to offset the current year gain, the income tax expense on this transaction was revised to €521 thousand as of December 31, 2022 (refer to the prior year consolidated financial statements). Figures are shown after the stock split. 06/30/2022 06/30/2023 (6 months) (6 months) Net loss (in thousands of euros) (1,024) (12,201) Weighted number of shares for the period (1) 3,101,605 3,284,500 Basic loss per share (€/share) (0.33) (3.71) Diluted loss per share (€/share) (0.33) (3.71) (1) after deduction of 250 treasury shares are held by the Company as treasury shares and recognized as a deduction of shareholders’ equity) and after taking into account the effect of the reverse share split (see Note 2.9). As of June 30, 2022 and 2023, the potential shares that could be issued (see Note 3.3.3) were not taken into consideration in the calculation of the diluted earnings, as their effect would be anti-dilutive.

NOTES RELATED TO THE CONSOLIDAT

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	6 Months Ended
	Jun. 30, 2023
Notes Related To The Consolidated Statements Of Financial Position [Abstract]
NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONFixed assetsIntangible assets other than goodwill (amounts in thousands of euros) Notes IP R&D and Other intangible assets GROSS VALUE As of December 31,2022 1,668 Business combination 4.1.2 17,098 Increase — Decrease — FX rate impact — Reclassification — As of June 30, 2023 18,766 ACCUMULATED AMORTIZATION AND IMPAIRMENT As of December 31,2022 (1,663) Increase (2) Decrease — FX rate impact — As of June 30, 2023 (1,665) NET VALUE As of December 31, 2022 5 As of June 30, 2023 17,101 Accounting Policy The Company accounts for business combinations using the acquisition method when the acquired set of activities and assets meets the definition of a business and control is transferred to the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of acquired businesses are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Transaction costs are expensed as incurred. If share-based payment awards (replacement awards) are required to be exchanged for awards held by the acquiree's employees (acquiree's awards), then all or a portion of the amount of the acquirer's replacement awards is included in measuring the consideration transferred in the business combination. This determination is based on the market-based measure of the replacement awards compared with the market-based measure of the acquiree's awards and the extent to which the replacement awards relate to pre-combination service . On June 23, 2023, ERYTECH acquired 100% of the shares and voting interests in Pherecydes Pharma S.A. in exchange for the Company’s shares. The Company determined it obtained control of Pherecydes Pharma and it is the accounting acquirer as this date. On the same date, Pherecydes Pharma S.A. was merged into the Company. Taking control of Pherecydes Pharma S.A. will enable the Company to work towards becoming a global leader in phage therapy and other medical needs caused by antimicrobial resistance. Contribution of Pherecydes Pharma S.A. to the Company’s total expenses and net loss for the six months ended June 30, 2023 is immaterial. If the acquisition had occurred on January 1, 2023, management estimates that consolidated loss for the 6 months ended June 30, 2023 would have been approximately €17.9M. This increase in consolidated loss relates mainly to operating expenses net of research tax credit income. A. Consideration transferred (acquisition price) The following table summarizes the acquisition date fair value of each major class of consideration transferred. (In thousands of Euros) Note Equity instruments i 24,642 Replacement share-based payment awards ii 436 Total consideration transferred (acquisition price) 25,078 i. Equity instruments issued (numbers presented before the reverse stock split) The fair value of the ordinary shares issued was based on the listed share price of the Company; Number of shares Share price Value (€ thousands) Shares issued on May 15, 2023 3,101,745 0.95 2,956 Shares issued on June 23, 2023 26,575,894 0.82 21,686 Total 29,677,639 24,642 Consideration transferred to obtain control was made in 2 installments, the first on May 15, 2023 at an Erytech share price of €0.95, and the second on June 23, 2023 at an Erytech share price of €0.82. ii. Replacement share-based payment awards ln accordance with the terms of the acquisition agreement, the Group exchanged equity-settled share-based payment awards held by employees of Pherecydes Pharma S.A. (the acquiree's awards) for equity settled share-based payment awards of the Company (the replacement awards). Refer to note 3.3.3 for details of the replacement awards. The portion of the amount of the acquirer's replacement awards included in the measurement of the consideration transferred amounts to €436 thousand. The portion of the amount of the acquirer's replacement awards included as a share-based payment expense for the 6 months ended June 30, 2023 amounts to €436 thousand. B. Acquisition-related costs The total acquisition costs incurred amount to €3,413 thousand and are included in general and administrative expenses (see note 3.3.2). C. Fair value of identifiable assets acquired and liabilities assumed at acquisition date (in thousands of euros) Note 06/30/2023 IFRS Intangible assets 4.1.1 17,098 Property, plant and equipment 4.1.3 485 Rights of use 4.2 478 Other non-current assets 83 Other current assets 1,925 Cash and cash equivalents 30 Financial liabilities 4.6 (2,936) Lease obligations 4.7 (456) Other non-current liabilities (49) Other current liabilities (5,085) Net assets acquired 11,575 i. Measurement of fair values The valuation techniques used for measuring the fair value of the IP R&D was a discounted cash-flow model. The fair value is estimated as the present value of net cash flows expected to be generated by the intellectual property of two identified R&D projects. The provisional fair value amount of Pherecydes Pharma's assets includes the valuation of in progress research and development recorded under intangible assets in the amount of €17,070 thousand: • IP osteoarticular infections on prostheses (PJI) for €14,404 thousand ; • IP endocarditis (EnDoCom) for €2,666 thousand. Fair values measured on a provisional basis The fair value of Pherecydes Pharma's intangible assets (IP R&D) has been measured provisionally, pending completion of an independent valuation at of the acquisition date. If new information obtained within one year of the date of acquisition about facts and circumstances that existed at the date of acquisition identifies adjustments to the above amounts, or any additional provisions that existed at the date of acquisition, then the accounting for the acquisition will be revised. D. Provisional Goodwill Provisional Goodwill arising from the acquisition has been recognized as follows: (In thousands of Euros) Note Consideration transferred (acquisition price) A 25,078 Fair value of identifiable net assets C -11,575 Provisional Goodwill 13,503 (amounts in thousands of euros) General equipment, fixtures and fittings Plant, equipment and tooling Office equipment and computers Assets under construction TOTAL GROSS VALUE As of December 31,2022 2,914 3,111 750 — 6,775 Business combination 346 110 29 — 485 Increase 0 53 0 — 53 Decrease (155) 0 0 — (155) FX rate impact (2) (2) (1) — (5) Reclassification 0 0 0 — 0 As of June 30, 2023 3,103 3,272 778 — 7,155 ACCUMULATED DEPRECIATION AND IMPAIRMENT As of December 31, 2022 (2,701) (2,957) (725) — (6,383) Depreciation (16) (49) (9) — (74) Impairment — — — — — Decrease 155 — — — 155 FX rate impact 2 1 — — 3 Reclassification — — — — — As of As of June 30, 2023 (2,560) (3,005) (734) — (6,299) NET VALUE As of December 31, 2022 213 154 25 — 393 As of June 30, 2023 543 267 44 — 857 The main changes in the first half of 2023 relate to the business combination with Pherecydes Pharma, with a value of €485 thousand. (amounts in thousands of euros) Buildings Plant, equipment and tooling Transport equipment Office equipment and computers TOTAL GROSS VALUE As of December 31, 2022 5,673 954 119 118 6,864 Business combination 205 273 478 Increase 17 17 Decrease — FX rate impact — Reclassification — As of June 30, 2023 5,878 1,227 136 118 7,359 ACCUMULATED DEPRECIATION AND IMPAIRMENT As of December 31, 2022 (3,116) (954) (92) (118) (4,280) Increase (210) (13) (223) Decrease 87 — — — 87 FX rate impact — — — — — Reclassification 0 — — — — As of June 30, 2023 (3,239) (954) (105) (118) (4,416) NET VALUE As of December 31, 2022 2,557 — 27 — 2,584 As of June 30, 2023 2,639 273 31 — 2,943 The remaining right of use net book value of €2,943 thousand is mainly related to the Bioserra building lease in Lyon (France) for €2,433 thousand. Business combination additions relate to leases acquired in connection with the merger with Pherecydes (see Note 4.1.2) and include: • Nantes premises for €64K; • Roussel premises for €141K; • Research equipment for €205K. (amounts in thousands of euros) 12/31/2022 6/30/2023 Trade and other receivables 76 245 Total current trade receivables 76 245 Research Tax Credit 1,484 2,603 Other receivables (including tax and social receivables) 973 1,251 Net investment in a sublease 43 0 Deposits related to leased premises 121 (40) Advance payments and deposits to suppliers 342 342 Prepaid expenses 805 1,331 Total other current assets 3,769 5,488 Research Tax Credit The Company benefits from the provisions in Articles 244 quater B and 49 septies F of the French Tax Code related to the Research Tax Credit. As of June 30, 2023, the CIR receivables included Research Tax Credit of €1,484 thousand for the 2022 financial year, €243 thousand for the CIR estimate for the first half of 2023 and €876 thousand from Pherecydes merger (CIR estimate for the first half 2023). Prepaid expenses As of December 31, 2022 and June 30, 2023, prepaid expenses are mainly related to insurance expense. (amounts in thousands of euros) 12/31/2022 06/30/2023 Current account 26,676 13,105 Term deposits 12,113 12,084 Total cash and cash equivalents as reported in statement of financial position 38,789 25,189 Bank overdrafts — — Total cash and cash equivalents as reported in statement of cash flow 38,789 25,189 As of December 31, 2022 and June 30, 2023, term deposits included a term deposit of €12 million with a maturity of one month and deposits of €0.1 million convertible into cash immediately. As of June 30, 2023, the Parent company's share capital comprised 6,075,105 shares (60,751,053 shares before reverse share split, see Note 2.9), fully paid up, with a nominal value of 1.00 euro. During the first half of 2023, the Company carried out the following capital increases (adjusted for the effects of the reverse share split): • May 2023, issue of 3,101,745 ordinary shares before reverse share split • June 2023, issue of 26,630,756 ordinary shares before reverse share split (amounts in thousands of euros) Convertible notes Conditional advances Bank loans Other Total As of December 31, 2022 — — 10,071 41 10,112 Business combination — 603 2,313 2,916 Increase — — 12 — 12 Fair value of embedded derivatives — Amortized cost — Conversion — Extinguishment of conditional advance — Repayment — — (1,243) (39) (1,282) FX rate impact (3) (3) As of June 30, 2023 — 603 11,153 (1) 11,753 Financial liabilities by maturity June 30, 2023 (in thousands of euros) Less than one year One to three years Three to five years More than five years Total Convertible notes — — — — — Conditional advances 121 481 — — 603 Bank loans 3,198 6,784 1,169 — 11,151 Other 1 — — — 1 Total financial liabilities 3,321 7,265 1,169 — 11,753 The €603 thousand business combination increase in conditional advances is due to the acquisition of Pherecydes, and concerns the Phagogram project (€118 thousand), the E.Coli project (€169 thousand) and the Phagosclin project (€345 thousand). Amounts resulting from the advantage of the conditional advance not bearing interest at a market rate are considered as grants. The impact on Pherecydes contracts is €29 thousand. (in thousands of euros) Lease Liabilities As of December 31, 2022 3,455 Business combination 456 Increase without cash impact 17 Repayment (414) Decrease without cash impact (127) FX rate impact (1) Capitalized interests — Reclassification — As of June 30, 2023 3,387 Lease liabilities by maturity (in thousands of euros) Less than one year One to three years Three to five years More than five years Total As of June 30, 2023 828 1,255 1,303 0 3,387 (amounts in thousands of euros) 12/31/2022 06/30/2023 Vendors 1,562 4,336 Vendors - accruals 3,553 4,785 Total trade and other payables 5,115 9,121 Social liabilities, taxation and social security 2,799 3,554 Fixed assets payables — — Deferred revenue 51 420 Other payables 59 59 Total other current liabilities 2,909 4,033 The increase in trade and other payables is mostly due to a €3,300 thousand increase resulting from the merger with Pherecydes. The increase in other current liabilities include a €1,339 thousand increase in accrued social and tax liabilities and a €416 thousand increase in deferred revenue resulting from the merger with Pherecydes. As of December 31, 2022 Carrying amount on the statement of financial position (1) Fair value through profit and loss Fair value through other comprehensive income Financial assets at amortized cost Financial liabilities at amortized cost Fair value Other non-current financial assets 195 195 195 Other current financial assets 464 464 464 Trade and other receivables 76 76 76 Other current assets 1,798 1,798 1,798 Cash and cash equivalents (2) 38,789 38,789 38,789 Total financial assets 41,322 38,789 — 2,533 — 41,322 Financial liabilities - non current portion (3) 7,547 7,547 7,547 Lease liabilities - non current portion (4) 2,680 2,680 2,680 Financial liabilities - current portion (3) 2,565 2,565 2,565 Lease liabilities - current portion (4) 775 775 775 Trade and other payables 5,115 5,115 5,115 Other current liabilities (6) 2,858 2,858 2,858 Total financial liabilities 21,540 — — — 21,540 21,540 As of June 30, 2023 Carrying amount on the statement of financial position (1) Fair value through profit and loss Fair value through other comprehensive income Financial assets at amortized cost Financial liabilities at amortized cost Fair value Other non-current financial assets 205 205 205 Other current financial assets 302 302 302 Trade and other receivables 245 245 245 Other current assets 3,854 3,854 3,854 Cash and cash equivalents (2) 25,189 25,189 25,189 Total financial assets 29,795 25,189 — 4,606 — 29,795 Financial liabilities - non current portion (3) 8,552 8,552 8,552 Lease liabilities - non current portion (4) 2,559 2,559 2,559 Financial liabilities - current portion (3) 3,201 3,201 3,201 Lease liabilities - current portion (4) 828 828 828 Trade and other payables 9,120 9,120 9,120 Other current liabilities (5) 3,613 3,613 3,613 Total financial liabilities 27,873 — — — 27,873 27,873 (1) The carrying amount of these assets and liabilities is a reasonable approximation of their fair value. (2) Cash and cash equivalents are comprised of money market funds and time deposit accounts, which are measured using level 1 measurements. (3) The fair value of financial liabilities is determined using level 2 measurements. (4) The fair value of lease liabilities is determined using level 2 measurements. (5) Excluding current liabilities accruals

CONTINGENCIES

CONTINGENCIES	6 Months Ended
	Jun. 30, 2023
Contingencies [Abstract]
CONTINGENCIES	CONTINGENCIES On June 5, 2023, ERYTECH Pharma announced that Akkadian Partners had initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23, 2023. On June 14, 2023, the Lyon Commercial Court rejected Akkadian's request to postpone the vote on the merger with PHERECYDES Pharma and ordered the appointment of a second judicial expert to assess the merger share ratio. On June 20, 2023, Akkadian Partners initiated new legal proceedings requesting the cancellation of the capital increase that occurred on May 15, 2023. On June 23, 2023, the merger with PHERECYDES was approved by the ERYTECH Pharma shareholders at the Combined General Meeting. On June 27,2023 and July 28, 2023, Akkadian Partners initiated two other legal proceedings to contest the votes of certain Shareholder's of ERYTECH and request the cancellation of the merger as voted in the combined General Meeting. The Group considers at this stage, based on its legal assessment of these procedures, that it is possible, but not probable, that these procedures will succeed. Accordingly, no provision for any liability has been made in these financial statements.

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2023
Disclosure of transactions between related parties [abstract]
RELATED PARTIES	RELATED PARTIESThe Company’s related parties for the first semester (until the merger approved on June 23, 2023) include the Chairman of the Board of Directors (Jean-Paul Kress), the Chief Executive Officer (Gil Beyen), the two Deputy General Managers (Jérôme Bailly and Eric Soyer), members of the Board of Directors and members of the executive committee. The remuneration of directors and members of the executive committee was as set forth in the table below. 06/30/2022 06/30/2023 (amounts in thousands of euros) Salary / fees Retirement benefits Share based payments Salary / fees Retirement benefits Share based payments Executive officers / VP and qualified person 630 110 222 875 11 136 Executive committee 993 61 20 368 8 (169) Board of directors 193 156 — — Total 1,816 171 242 1,399 19 (33) On June 23, 2023 following the merger, a new governance structure was implemented, with Didier Hoch as Chairman of the Board of Directors, Gil Beyen as Vice Chairman, Thibaut du Fayet as Chief Executive Officer and two Deputy General Managers (Jérôme Bailly and Eric Soyer) and members of the Board of Directors and members of the executive committee. On June 23, 2023, the Board of Directors authorized the agreements and commitments listed below and covered by Articles L. 225-38 et seq. of the French Commercial Code in favor of Mr. Thibaut du Fayet, the Company's Chief Executive Officer: • Severance pay equal to twelve times the average monthly remuneration received during the twelve months preceding the revocation decision or the expiry of the term of office, subject to performance conditions; • Additional retirement agreement: the contributions financing the additional retirement agreement with defined contributions would be entirely assumed by the Company; • Health insurance: the Company will pay 60% of the total monthly contribution to the health insurance scheme, in accordance with the established agreement; • Death, disability and incapacity coverage: • General scheme: the Company will pay 60% of contributions to the general employee benefits scheme. • Supplementary retirement plan: 50% of the contributions to the supplementary retirement plan will be paid by the Company. • Additional provident fund: contributions to finance the supplementary benefit plan will be fully paid by the Company. As a result of a termination or change of duties,the Chief Executive Officer and the two Deputy General Managers, could receive a compensation equal to their remuneration during the last 12 months, as well as non-competition indemnities of up to 18 months salary. The Company has no other related parties.

OFF-BALANCE SHEET COMMITMENTS

OFF-BALANCE SHEET COMMITMENTS	6 Months Ended
	Jun. 30, 2023
Disclosure Of Off Balance Sheet Commitments [Abstract]
OFF-BALANCE SHEET COMMITMENTS	OFF-BALANCE SHEET COMMITMENTS Collaborative arrangements Agreement with SQZ Biotechnologies On June 24, 2019, the Company entered into a collaboration agreement with SQZ Biotechnologies, a cell therapy company developing novel treatments in multiple therapeutic areas, to advance novel red blood cell-based therapeutics for immune modulation. Under the terms of the agreement, the Company has granted to SQZ Biotechnologies an exclusive worldwide license to develop antigen specific immune modulating therapies employing red blood cell-based approaches. Combining SQZ Biotechnologies’ proprietary and versatile cell engineering platform with the intellectual property of the Company related to red blood cell-based therapeutics is intended to allow for the rapid development of a broad pipeline of novel immunomodulatory products addressing multiple indications. The agreement provides for: • An upfront payment of $1 million, equivalent to €0.9 million when recognized in 2019; • Potential development, regulatory and commercial milestone payments up to $56 million for the first product successfully developed by SQZ Biotechnologies under this agreement; • The Company could also receive progressive royalties based on future sales. Lease agreements Sublease in the United-States In July 2019 and June 2021, the Company signed two sublease agreements for its premises located in Cambridge. The sublease in the US ended in January 2023.

ACCOUNTING RULES AND METHODS (P

ACCOUNTING RULES AND METHODS (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Rules And Methods [Abstract]
Basis of preparation	Basis of preparation The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with the underlying assumption of going concern assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern. The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the products developed, therefore involving a multi-year research and development phase. The Company has historically financed its growth by strengthening its equity in the form of capital increases and issuance of convertible notes. At the date the Board of Directors authorized the unaudited interim condensed consolidated financial statements the Company has the necessary resources to fund its operations into the second quarter 2024 considering: • Cash and cash equivalents held by the Company amounted to €25.2 million as of June 30, 2023. They are composed of cash and term deposits readily available without penalty; • The cash consumption forecast for the next 12 months after the closing date. Accordingly, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern. Therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. The Company plans to seek additional financing to extend its cash flow horizon and is currently evaluating various financing sources among which are the issuance of equity instruments and/or new debt or partnership agreements to continue to fund the operations of the Company beyond the second quarter of 2024.
Statement of compliance	Statement of compliance The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with IAS 34, the standard of the International Financial Reporting Standards (“ IFRS ”) as issued by the International Accounting Standard Board (“ IASB ”) applicable to interim financial statements and were authorized for issuance by the Board of Directors of the Company on September 21, 2023. Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the Unaudited Interim Condensed Consolidated Financial Statements of the Company are also prepared in accordance with IAS 34, as adopted by the European Union (EU). As condensed consolidated financial statements, they do not include all information that would be required by the full IFRS standards. They must be read in conjunction with the consolidated financial statements for the year ended December 31, 2022. The standards applied in the preparation of the Unaudited Interim Condensed Consolidated Financial Statements are the same as those applied to prepare the financial statements as of December 31, 2022, except as described below. As of June 30, 2023, all IFRS that the IASB had published and that are mandatory are the same as those endorsed by the EU and mandatory in the EU. As a result, the Unaudited Interim Condensed Consolidated Financial Statements comply with International Financial Reporting Standards as published by the IASB and as adopted by the EU. IFRS include International Financial Reporting Standards (“ IFRS ”), International Accounting Standards (“ IAS ”), as well as the interpretations issued by the Standing Interpretations Committee (“ SIC ”), and the International Financial Reporting Interpretations Committee (“ IFRS IC ”). The new applicable standards, amendments and interpretations since January 1, 2023 have had no significant impact on the Company’s consolidated financial statements. Recently issued accounting pronouncements that may be relevant to the Company’s operations are as follows: • Amendments to IAS 1 - Classification of liabilities as current or non-current ; Disclosure of Accounting Policies, effective on January 1, 2024; • Amendments to IAS 8 - Definition of Accounting Estima tes, effective on January 1, 2023; • Amendment to IAS12 - Deferred Tax related to Assets and Liabilities arising from a Single Transaction, , effective on January 1, 2023; The Company does not expect any significant impact resulting from the adoption of these standards.
Basis of consolidation	Basis of consolidation In accordance with IFRS 10 Consolidated Financial Statements (“ IFRS 10 ”), an entity is consolidated when it is controlled by the Company. The Company controls an entity when it is exposed or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. All intercompany balances, transactions and dividends are eliminated in full. The Company has one subsidiary for which no non-controlling interest is recognized. Date of Incorporation Percent of Ownership Interest Accounting Method ERYTECH Pharma, Inc. April 2014 100% Consolidated
Foreign currencies	Foreign currencies Functional Currency and Translation of Financial Statements into Presentation Currency The Unaudited Interim Condensed Consolidated Financial Statements are presented in euros, which is also the functional currency of the parent company, PHAXIAM Therapeutics (the “ Parent Company ”). The statement of financial position of the consolidated entity having a functional currency different from the euro are translated into euros at the closing exchange rate (spot exchange rate at the statement of financial position date) and the statement of income (loss), statement of comprehensive income (loss) and statement of cash flow of such consolidated entity are translated at the average exchange rate for the period, except if exchange rates or the volume and size of transactions fluctuate significantly. The resulting translation adjustment is included in other comprehensive income (loss) as a cumulative translation adjustment. Exchange rate (USD per EUR) 06/30/2022 12/31/2022 06/30/2023 Weighted average rate 1.0940 1.0539 1.0811 Closing rate 1.0387 1.0666 1.0866 Conversion of Foreign Currency Transactions Foreign currency transactions are converted to functional currency at the exchange rate applicable on the transaction date. At the closing date, foreign currency monetary assets and liabilities are converted at the exchange rate prevailing on that date. The resulting exchange gains or losses are recorded in the consolidated statement of income (loss) in “Financial income (loss)”.
Use of estimates and judgments	Use of estimates and judgments Preparation of the consolidated financial statements in accordance with the rules prescribed by the IFRS requires the use of estimates and the formulation of assumptions having an impact on the financial statements. These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The Company has not identified any environmental risks that would require significant new estimates or judgments. The use of estimates and judgment relate primarily to the measurement of: • fair value of in progress research and developments assets identified in business combination (see Note 4.1.1 and 4.1.2) • the share-based payments in accordance with IFRS 2 (see note 3.3.3)
Presentation of the statement of income (loss) & statement of financial position	Presentation of the statement of income (loss) & statement of financial positionThe Company presents its statement of income (loss) by function. As of today, the main activity of the Company is research and development. Consequently, only “research and development expenses” and “general administrative expenses” functions are considered to be representative of the Company's activities. The detail of the expenses by nature is disclosed in note 3.2.
Presentation of the statement of cash flows	Presentation of the statement of cash flowsThe consolidated statements of cash flows are prepared using the indirect method and separately present the cash flows associated with operating, investing, and financing activities.
Segment reporting	Segment reporting In accordance with IFRS 8 Operating Segments ( "IFRS 8" ) , reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Chief Executive Officer) to allocate resources and to assess performance.
Business combination	Accounting Policy The Company accounts for business combinations using the acquisition method when the acquired set of activities and assets meets the definition of a business and control is transferred to the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of acquired businesses are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Transaction costs are expensed as incurred. If share-based payment awards (replacement awards) are required to be exchanged for awards held by the acquiree's employees (acquiree's awards), then all or a portion of the amount of the acquirer's replacement awards is included in measuring the consideration transferred in the business combination. This determination is based on the market-based measure of the replacement awards compared with the market-based measure of the acquiree's awards and the extent to which the replacement awards relate to pre-combination service .

ACCOUNTING RULES AND METHODS (T

ACCOUNTING RULES AND METHODS (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Rules And Methods [Abstract]
Summary of Details of the Company's Subsidiary	Date of Incorporation Percent of Ownership Interest Accounting Method ERYTECH Pharma, Inc. April 2014 100% Consolidated
Summary of Accounting Policy for Exchange Rates	Exchange rate (USD per EUR) 06/30/2022 12/31/2022 06/30/2023 Weighted average rate 1.0940 1.0539 1.0811 Closing rate 1.0387 1.0666 1.0866
Summary of Geographical Segment Information	Information per geographical segment Income from external customers (amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) France 0 0 United States 54 7 Total 54 7

NOTES RELATED_TO THE UNAUDITE_2

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure Of Detailed Information Of Operating Income Loss [Abstract]
Summary of Detailed Information of Operating Income	(amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) Research Tax Credit 860 243 Subsidies 40 28 Income from licenses or other contracts 54 7 Net gain on disposal of tangible assets 24,351 — Total 25,304 278
Summary of Operating Expense by Nature	For the six months ended June 30, 2022 (amounts in thousands of euros) R&D Regulatory Clinical studies Total Consumables 0 450 450 IT costs and maintenance 66 765 831 Services, subcontracting and fees 237 723 3,128 4,088 Personnel expenses 785 467 7,110 8,362 Depreciation, amortization & impairment 178 3,443 3,621 Other 7 (59) (52) Total 1,273 1,190 14,837 17,300 For the six months ended June 30, 2023 (amounts in thousands of euros) R&D Regulatory Clinical studies Total Consumables 128 0 101 229 IT costs and maintenance (14) 2 113 101 Services, subcontracting and fees 210 (144) 228 294 Personnel expenses 911 348 1,381 2,640 Depreciation, amortization & impairment 209 0 (58) 151 Other 0 0 16 16 Total 1,444 206 1,781 3,431 (amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) Consumables 57 47 IT Costs and maintenance 175 442 Services, subcontracting and fees 3,446 5,664 Personnel expenses 3,288 2,957 Depreciation and amortization 669 (110) Other 277 246 Total 7,911 9,245
Summary of Personal Expenses	For the six months ended June 30, 2022 (amounts in thousands of euros) R&D Regulatory Clinical studies Total Wages and salaries 533 381 4,237 5,151 Share-based payments (employees and executive management) 17 (27) (10) Social security expenses 235 86 1,209 1,530 Restructuring charge 1,691 1,691 Total personnel expenses 785 467 7,110 8,362 For the six months ended June 30, 2023 (amounts in thousands of euros) R&D Regulatory Clinical studies Total Wages and salaries 603 287 1,047 1,937 Share-based payments (employees and executives) 33 0 114 147 Social security expenses 275 61 220 556 Total personnel expenses 911 348 1,381 2,640 (amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) Wages and salaries 2,051 2,082 Share-based payments (employees and executive management) 304 230 Social security expenses 766 645 Restructuring charge 167 Total personnel expenses 3,288 2,957
Summary of Assumptions Used to Determine Fair Value of Plans Granted	Plan BSPCE 2019-1 BSPCE 2019-2 BSPCE 2019-4 BSPCE 2021-2 BSPCE 2021-3 BSPCE 2021-4 Number of options 3,691 7,500 263 7,500 6,328 62,325 Exercise price €1.09 €0.92 €1.09 €1.60 €2.19 €1.89 Underlying price €0.00 €0.47 €0.46 €0.40 €0.34 (Tranche 3) €0.35 (Tranche 4) €0.37 Expected dividends — % — % — % — % — % — % Volatility 87.14% - 92.92% 87.01% - 98.86% 84.03% - 89.19% 82.99% - 88.93% 79.89% - 88.22% 80.52% - 88.06% Risk-free rate 3.0108% - 3.2655% 2.9750% - 3.2290% 2.8787% -3.1274% 2.8033% - 3.1269% 2.8517% - 3.0093% 2.8625% - 2.9676% Fair value of the plan (in K€) 0.00 3.53 0.12 3.00 4.37 23.06 - Free shares (“AGA”) plan Figures are shown after the reverse stock split. Erytech Number of shares 16,460 Plan AGA 2022 Underlying price €0.82 Expected dividends — % Maturity 1 year - 3 years Fair value of plan (in K€) 135
Breakdown of Expenses of Plans per Financial Year	Breakdown of expenses per financial year Plan name Amount in P&L in euros thousands as of June 30, 2022 of which employees of which executive officers and executive committee of which board members AGA 202 31 171 — BSA — — — — SO 124 53 71 — Total 326 84 242 — Plan name Amount in P&L in euros thousands as of June 30, 2023 of which employees of which executive officers and executive committee of which board members AGA 66 — 66 — BSPCE 435 222 104 109 SO (110) (123) 13 — Total 391 99 183 109
Summary of Financial income (loss)	(amounts in thousands of euros) 06/30/2022 06/30/2023 (6 months) (6 months) Income from short term deposits 6 171 Change in fair value of derivative liabilities — — Foreign exchange gains 3,348 137 Other financial income 16 23 Financial income 3,370 331 Amortized cost of convertible notes (22) — Financial expenses on lease liability (108) (25) Interest expense related to borrowings (140) (78) Foreign exchange loss (480) (239) Other financial expenses — — Financial expenses (750) (342) Financial income (loss) 2,620 (11)
Summary of Basic Earnings per Share and Diluted Earnings (Loss) per Share	06/30/2022 06/30/2023 (6 months) (6 months) Net loss (in thousands of euros) (1,024) (12,201) Weighted number of shares for the period (1) 3,101,605 3,284,500 Basic loss per share (€/share) (0.33) (3.71) Diluted loss per share (€/share) (0.33) (3.71) (1) after deduction of 250 treasury shares are held by the Company as treasury shares and recognized as a deduction of shareholders’ equity) and after taking into account the effect of the reverse share split (see Note 2.9).

NOTES RELATED TO THE CONSOLID_2

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Related To The Consolidated Statements Of Financial Position [Abstract]
Schedule of Intangibles Assets	(amounts in thousands of euros) Notes IP R&D and Other intangible assets GROSS VALUE As of December 31,2022 1,668 Business combination 4.1.2 17,098 Increase — Decrease — FX rate impact — Reclassification — As of June 30, 2023 18,766 ACCUMULATED AMORTIZATION AND IMPAIRMENT As of December 31,2022 (1,663) Increase (2) Decrease — FX rate impact — As of June 30, 2023 (1,665) NET VALUE As of December 31, 2022 5 As of June 30, 2023 17,101
Summary of Business Combination	The following table summarizes the acquisition date fair value of each major class of consideration transferred. (In thousands of Euros) Note Equity instruments i 24,642 Replacement share-based payment awards ii 436 Total consideration transferred (acquisition price) 25,078 The fair value of the ordinary shares issued was based on the listed share price of the Company; Number of shares Share price Value (€ thousands) Shares issued on May 15, 2023 3,101,745 0.95 2,956 Shares issued on June 23, 2023 26,575,894 0.82 21,686 Total 29,677,639 24,642 (in thousands of euros) Note 06/30/2023 IFRS Intangible assets 4.1.1 17,098 Property, plant and equipment 4.1.3 485 Rights of use 4.2 478 Other non-current assets 83 Other current assets 1,925 Cash and cash equivalents 30 Financial liabilities 4.6 (2,936) Lease obligations 4.7 (456) Other non-current liabilities (49) Other current liabilities (5,085) Net assets acquired 11,575 Provisional Goodwill arising from the acquisition has been recognized as follows: (In thousands of Euros) Note Consideration transferred (acquisition price) A 25,078 Fair value of identifiable net assets C -11,575 Provisional Goodwill 13,503
Schedule of Property, Plant and Equipment	(amounts in thousands of euros) General equipment, fixtures and fittings Plant, equipment and tooling Office equipment and computers Assets under construction TOTAL GROSS VALUE As of December 31,2022 2,914 3,111 750 — 6,775 Business combination 346 110 29 — 485 Increase 0 53 0 — 53 Decrease (155) 0 0 — (155) FX rate impact (2) (2) (1) — (5) Reclassification 0 0 0 — 0 As of June 30, 2023 3,103 3,272 778 — 7,155 ACCUMULATED DEPRECIATION AND IMPAIRMENT As of December 31, 2022 (2,701) (2,957) (725) — (6,383) Depreciation (16) (49) (9) — (74) Impairment — — — — — Decrease 155 — — — 155 FX rate impact 2 1 — — 3 Reclassification — — — — — As of As of June 30, 2023 (2,560) (3,005) (734) — (6,299) NET VALUE As of December 31, 2022 213 154 25 — 393 As of June 30, 2023 543 267 44 — 857
Schedule of Right of Use	(amounts in thousands of euros) Buildings Plant, equipment and tooling Transport equipment Office equipment and computers TOTAL GROSS VALUE As of December 31, 2022 5,673 954 119 118 6,864 Business combination 205 273 478 Increase 17 17 Decrease — FX rate impact — Reclassification — As of June 30, 2023 5,878 1,227 136 118 7,359 ACCUMULATED DEPRECIATION AND IMPAIRMENT As of December 31, 2022 (3,116) (954) (92) (118) (4,280) Increase (210) (13) (223) Decrease 87 — — — 87 FX rate impact — — — — — Reclassification 0 — — — — As of June 30, 2023 (3,239) (954) (105) (118) (4,416) NET VALUE As of December 31, 2022 2,557 — 27 — 2,584 As of June 30, 2023 2,639 273 31 — 2,943
Schedule of Trade Receivables and Other Current Assets	(amounts in thousands of euros) 12/31/2022 6/30/2023 Trade and other receivables 76 245 Total current trade receivables 76 245 Research Tax Credit 1,484 2,603 Other receivables (including tax and social receivables) 973 1,251 Net investment in a sublease 43 0 Deposits related to leased premises 121 (40) Advance payments and deposits to suppliers 342 342 Prepaid expenses 805 1,331 Total other current assets 3,769 5,488
Summary of Cash and Cash Equivalents	(amounts in thousands of euros) 12/31/2022 06/30/2023 Current account 26,676 13,105 Term deposits 12,113 12,084 Total cash and cash equivalents as reported in statement of financial position 38,789 25,189 Bank overdrafts — — Total cash and cash equivalents as reported in statement of cash flow 38,789 25,189
Summary of Financial Liabilities by Type	(amounts in thousands of euros) Convertible notes Conditional advances Bank loans Other Total As of December 31, 2022 — — 10,071 41 10,112 Business combination — 603 2,313 2,916 Increase — — 12 — 12 Fair value of embedded derivatives — Amortized cost — Conversion — Extinguishment of conditional advance — Repayment — — (1,243) (39) (1,282) FX rate impact (3) (3) As of June 30, 2023 — 603 11,153 (1) 11,753
Summary of Financial Liabilities by Maturity	Financial liabilities by maturity June 30, 2023 (in thousands of euros) Less than one year One to three years Three to five years More than five years Total Convertible notes — — — — — Conditional advances 121 481 — — 603 Bank loans 3,198 6,784 1,169 — 11,151 Other 1 — — — 1 Total financial liabilities 3,321 7,265 1,169 — 11,753
Summary of Lease liabilities	(in thousands of euros) Lease Liabilities As of December 31, 2022 3,455 Business combination 456 Increase without cash impact 17 Repayment (414) Decrease without cash impact (127) FX rate impact (1) Capitalized interests — Reclassification — As of June 30, 2023 3,387
Summary of Lease Liabilities By Maturity	Lease liabilities by maturity (in thousands of euros) Less than one year One to three years Three to five years More than five years Total As of June 30, 2023 828 1,255 1,303 0 3,387
Summary of Trade Payables and Other Current Liabilities	(amounts in thousands of euros) 12/31/2022 06/30/2023 Vendors 1,562 4,336 Vendors - accruals 3,553 4,785 Total trade and other payables 5,115 9,121 Social liabilities, taxation and social security 2,799 3,554 Fixed assets payables — — Deferred revenue 51 420 Other payables 59 59 Total other current liabilities 2,909 4,033
Summary of Financial Instruments Recognized in the Consolidated Statement of Financial Position	As of December 31, 2022 Carrying amount on the statement of financial position (1) Fair value through profit and loss Fair value through other comprehensive income Financial assets at amortized cost Financial liabilities at amortized cost Fair value Other non-current financial assets 195 195 195 Other current financial assets 464 464 464 Trade and other receivables 76 76 76 Other current assets 1,798 1,798 1,798 Cash and cash equivalents (2) 38,789 38,789 38,789 Total financial assets 41,322 38,789 — 2,533 — 41,322 Financial liabilities - non current portion (3) 7,547 7,547 7,547 Lease liabilities - non current portion (4) 2,680 2,680 2,680 Financial liabilities - current portion (3) 2,565 2,565 2,565 Lease liabilities - current portion (4) 775 775 775 Trade and other payables 5,115 5,115 5,115 Other current liabilities (6) 2,858 2,858 2,858 Total financial liabilities 21,540 — — — 21,540 21,540 As of June 30, 2023 Carrying amount on the statement of financial position (1) Fair value through profit and loss Fair value through other comprehensive income Financial assets at amortized cost Financial liabilities at amortized cost Fair value Other non-current financial assets 205 205 205 Other current financial assets 302 302 302 Trade and other receivables 245 245 245 Other current assets 3,854 3,854 3,854 Cash and cash equivalents (2) 25,189 25,189 25,189 Total financial assets 29,795 25,189 — 4,606 — 29,795 Financial liabilities - non current portion (3) 8,552 8,552 8,552 Lease liabilities - non current portion (4) 2,559 2,559 2,559 Financial liabilities - current portion (3) 3,201 3,201 3,201 Lease liabilities - current portion (4) 828 828 828 Trade and other payables 9,120 9,120 9,120 Other current liabilities (5) 3,613 3,613 3,613 Total financial liabilities 27,873 — — — 27,873 27,873 (1) The carrying amount of these assets and liabilities is a reasonable approximation of their fair value. (2) Cash and cash equivalents are comprised of money market funds and time deposit accounts, which are measured using level 1 measurements. (3) The fair value of financial liabilities is determined using level 2 measurements. (4) The fair value of lease liabilities is determined using level 2 measurements. (5) Excluding current liabilities accruals

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of transactions between related parties [abstract]
Summary of Remuneration of Directors and Members of the Executive Committee	The remuneration of directors and members of the executive committee was as set forth in the table below. 06/30/2022 06/30/2023 (amounts in thousands of euros) Salary / fees Retirement benefits Share based payments Salary / fees Retirement benefits Share based payments Executive officers / VP and qualified person 630 110 222 875 11 136 Executive committee 993 61 20 368 8 (169) Board of directors 193 156 — — Total 1,816 171 242 1,399 19 (33)

DESCRIPTION OF THE BUSINESS (De

DESCRIPTION OF THE BUSINESS (Details) € in Thousands, $ in Millions	1 Months Ended
	Apr. 30, 2022 EUR (€) employee	Apr. 30, 2022 USD ($) employee	Nov. 30, 2017 EUR (€)	Nov. 30, 2017 USD ($)	May 31, 2013 EUR (€)	Jun. 30, 2023 EUR (€)	May 15, 2023 shares	Apr. 13, 2023	Dec. 31, 2022 EUR (€)	Jun. 30, 2022 EUR (€)	May 25, 2022 tranch	Dec. 31, 2021 EUR (€)
Disclosure Of Description Of Business [Line Items]
Initial public offering amount			€ 124,000	$ 144	€ 17,700
Shareholders' equity | €						€ 36,632			€ 23,487	€ 22,436		€ 22,845
Percentage of Company's share capital, threshold								5%
Proceeds from sales of property, plant and equipment, classified as investing activities, net of transactions costs	€ 40,700	$ 44.5
Number of employees who received employment offer | employee	40	40
Net gain on disposal of property, plant, and equipment	€ 3,000	$ 3.3
Number of positions dismissed | tranch											52
Total number of positions at date of plan | tranch											109
Cell Therapy Manufacturing Facility
Disclosure Of Description Of Business [Line Items]
Gains on disposals of property, plant and equipment	€ 24,300	$ 26.6
Erytech and Pherecydes Merger
Disclosure Of Description Of Business [Line Items]
Shares received for every four shares (in shares)							15
Shares issued in relation to shares owned (in shares)							4
Shares contributed (in shares)							827,132
Shares issued (in shares)							3,101,745
Akkadian Partners Fund
Disclosure Of Description Of Business [Line Items]
Percentage of Company's share capital								5.06%
Percentage of Company's voting rights								4.83%

ACCOUNTING RULES AND METHODS -

ACCOUNTING RULES AND METHODS - Additional Information (Details) € / shares in Units, € in Thousands		6 Months Ended
	Jul. 27, 2023 € / shares	Jun. 30, 2023 EUR (€) subsidiary € / shares	Sep. 18, 2023 shares	Jul. 26, 2023 € / shares	Dec. 31, 2022 EUR (€)
Disclosure of geographical areas [line items]
Cash and cash equivalents | €		€ 25,189			€ 38,789
Number of subsidiaries | subsidiary		1
Par value per share (in euro per share) | € / shares		€ 1
Reverse Stock Split
Disclosure of geographical areas [line items]
Par value per share (in euro per share) | € / shares	€ 1			€ 0.10
Stock split ratio, common stock	0.1
Number of shares outstanding (in shares) | shares			60,751,054
Number of shares issued (in shares) | shares			6,075,105

ACCOUNTING RULES AND METHODS _2

ACCOUNTING RULES AND METHODS - Summary of Details of the Company's Subsidiary (Details)	6 Months Ended
	Jun. 30, 2023
ERYTECH Pharma, Inc.
Disclosure of subsidiaries [line items]
Percent of Ownership Interest	100%

ACCOUNTING RULES AND METHODS _3

ACCOUNTING RULES AND METHODS - Summary of Accounting Policy for Exchange Rates (Details) - uSD_per_EUR	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Accounting Rules And Methods [Abstract]
Weighted average rate	1.0811	1.0940	1.0539
Closing rate	1.0866	1.0387	1.0666

ACCOUNTING RULES AND METHODS _4

ACCOUNTING RULES AND METHODS - Summary of Information about Geographical Segment (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of geographical areas [line items]
Revenues from external customers	€ 7	€ 54
France
Disclosure of geographical areas [line items]
Revenues from external customers	0	0
United States
Disclosure of geographical areas [line items]
Revenues from external customers	€ 7	€ 54

NOTES RELATED_TO THE UNAUDITE_3

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) - Additional Information (Details) € in Thousands, $ in Thousands					1 Months Ended		6 Months Ended
	Jun. 23, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Apr. 22, 2022 EUR (€)	Apr. 22, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 EUR (€) employee shares	Jun. 30, 2022 EUR (€) employee	Apr. 22, 2022 USD ($)
Disclosure of detailed information of operating income loss [line items]
Disposal of property, plant and equipment							€ 0	€ 37,630
Property, plant and equipment		€ 393					857
Right of use		2,584					2,943
Decrease in research and development expenses							13,900
Increase in general and administrative expenses							1,330
Merger costs	€ 3,413						€ 3,410
Outstanding equity instruments (in shares) | shares							396,318
Tax expense (income)		€ 521			€ 3,737	$ 4,086	€ (208)	€ 3,737
Research and development expenses
Disclosure of detailed information of operating income loss [line items]
Decrease in services and subcontracting expenses							3,800
Decrease in personnel expenses							€ 5,700
Average number of employees | employee							27	117
Restructuring charge								€ 1,691
Decrease in depreciation							€ 3,500
Impairment								€ 2,100
General and administrative expenses
Disclosure of detailed information of operating income loss [line items]
Decrease in services and subcontracting expenses							€ (2,200)
Average number of employees | employee							18	32
Restructuring charge								€ 167
Decrease in personnel expenses							€ (300)
Cell Therapy Manufacturing Facility
Disclosure of detailed information of operating income loss [line items]
Disposal of property, plant and equipment			€ 40,676	$ 44,500
Property, plant and equipment			15,673						$ 17,146
Intangible assets and goodwill			4						4
Right of use			3,022						3,307
Cancellation of lease obligation			5,419						5,928
Transaction costs			€ 3,046						$ 3,333

NOTES RELATED_TO THE UNAUDITE_4

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) - Summary of Detailed Information of Operating Income (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information of operating income loss [line items]
Total	€ 278	€ 25,304
Research tax credit
Disclosure of detailed information of operating income loss [line items]
Total	243	860
Subsidies and extinguishment of conditional advance
Disclosure of detailed information of operating income loss [line items]
Total	28	40
Income from licenses or other contracts
Disclosure of detailed information of operating income loss [line items]
Total	7	54
Net gain on disposal of tangible assets
Disclosure of detailed information of operating income loss [line items]
Total	€ 0	€ 24,351

NOTES RELATED_TO THE UNAUDITE_5

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) - Summary of Operating Expense (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Operating Expenses [Line Items]
Total	€ 12,676	€ 25,211
Research and development expenses
Disclosure Of Operating Expenses [Line Items]
Consumables	229	450
IT costs and maintenance	101	831
Services, subcontracting and fees	294	4,088
Personnel expenses	2,640	8,362
Depreciation, amortization & impairment	151	3,621
Other	16	(52)
Total	3,431	17,300
General and administrative expenses
Disclosure Of Operating Expenses [Line Items]
Consumables	47	57
IT costs and maintenance	442	175
Services, subcontracting and fees	5,664	3,446
Personnel expenses	2,957	3,288
Depreciation and amortization	(110)	669
Other	246	277
Total	9,245	7,911
R&D | Research and development expenses
Disclosure Of Operating Expenses [Line Items]
Consumables	128	0
IT costs and maintenance	(14)	66
Services, subcontracting and fees	210	237
Personnel expenses	911	785
Depreciation, amortization & impairment	209	178
Other	0	7
Total	1,444	1,273
Regulatory | Research and development expenses
Disclosure Of Operating Expenses [Line Items]
Consumables	0
IT costs and maintenance	2
Services, subcontracting and fees	(144)	723
Personnel expenses	348	467
Depreciation, amortization & impairment	0
Other	0
Total	206	1,190
Clinical studies | Research and development expenses
Disclosure Of Operating Expenses [Line Items]
Consumables	101	450
IT costs and maintenance	113	765
Services, subcontracting and fees	228	3,128
Personnel expenses	1,381	7,110
Depreciation, amortization & impairment	(58)	3,443
Other	16	(59)
Total	€ 1,781	€ 14,837

NOTES RELATED_TO THE UNAUDITE_6

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) - Summary of Personal Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Research and development expenses
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	€ 1,937	€ 5,151
Share-based payments (employees and executive management)	147	(10)
Social security expenses	556	1,530
Restructuring charge		1,691
Total personnel expenses	2,640	8,362
General and administrative expenses
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	2,082	2,051
Share-based payments (employees and executive management)	230	304
Social security expenses	645	766
Restructuring charge		167
Total personnel expenses	2,957	3,288
R&D | Research and development expenses
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	603	533
Share-based payments (employees and executive management)	33	17
Social security expenses	275	235
Restructuring charge
Total personnel expenses	911	785
Regulatory | Research and development expenses
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	287	381
Share-based payments (employees and executive management)	0
Social security expenses	61	86
Restructuring charge
Total personnel expenses	348	467
Clinical studies | Research and development expenses
Disclosure Of Employee Benefits Expense [Line Items]
Wages and salaries	1,047	4,237
Share-based payments (employees and executive management)	114	(27)
Social security expenses	220	1,209
Restructuring charge		1,691
Total personnel expenses	€ 1,381	€ 7,110

NOTES RELATED_TO THE UNAUDITE_7

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) - Summary of Assumptions Used to Determine Fair Value of Plans Granted (Details)	6 Months Ended
	Jun. 30, 2023 EUR (€) shares yr € / shares
Minimum
Disclosure of detailed information of operating income loss [line items]
Maturity | yr	1
Maximum
Disclosure of detailed information of operating income loss [line items]
Maturity | yr	3
BSPCE 2019-1
Disclosure of detailed information of operating income loss [line items]
Number of options granted (in shares) | shares	3,691
Exercise price (in euro per share)	€ 1.09
Price of underlying share (euro per share)	€ 0
Expected dividends	0%
Fair value of the plan (in K€) | €	€ 0
BSPCE 2019-1 | Minimum
Disclosure of detailed information of operating income loss [line items]
Volatility	87.14%
Risk-free rate	3.0108%
BSPCE 2019-1 | Maximum
Disclosure of detailed information of operating income loss [line items]
Volatility	92.92%
Risk-free rate	3.2655%
BSPCE 2019-2
Disclosure of detailed information of operating income loss [line items]
Number of options granted (in shares) | shares	7,500
Exercise price (in euro per share)	€ 0.92
Price of underlying share (euro per share)	€ 0.47
Expected dividends	0%
Fair value of the plan (in K€) | €	€ 3,530
BSPCE 2019-2 | Minimum
Disclosure of detailed information of operating income loss [line items]
Volatility	87.01%
Risk-free rate	2.975%
BSPCE 2019-2 | Maximum
Disclosure of detailed information of operating income loss [line items]
Volatility	98.86%
Risk-free rate	3.229%
BSPCE 2019-4
Disclosure of detailed information of operating income loss [line items]
Number of options granted (in shares) | shares	263
Exercise price (in euro per share)	€ 1.09
Price of underlying share (euro per share)	€ 0.46
Expected dividends	0%
Fair value of the plan (in K€) | €	€ 120
BSPCE 2019-4 | Minimum
Disclosure of detailed information of operating income loss [line items]
Volatility	84.03%
Risk-free rate	2.8787%
BSPCE 2019-4 | Maximum
Disclosure of detailed information of operating income loss [line items]
Volatility	89.19%
Risk-free rate	3.1274%
BSPCE 2021-2
Disclosure of detailed information of operating income loss [line items]
Number of options granted (in shares) | shares	7,500
Exercise price (in euro per share)	€ 1.60
Price of underlying share (euro per share)	€ 0.40
Expected dividends	0%
Fair value of the plan (in K€) | €	€ 3,000
BSPCE 2021-2 | Minimum
Disclosure of detailed information of operating income loss [line items]
Volatility	82.99%
Risk-free rate	2.8033%
BSPCE 2021-2 | Maximum
Disclosure of detailed information of operating income loss [line items]
Volatility	88.93%
Risk-free rate	3.1269%
BSPCE 2021-3
Disclosure of detailed information of operating income loss [line items]
Number of options granted (in shares) | shares	6,328
Exercise price (in euro per share)	€ 2.19
Expected dividends	0%
Fair value of the plan (in K€) | €	€ 4,370
BSPCE 2021-3 | Tranche three
Disclosure of detailed information of operating income loss [line items]
Price of underlying share (euro per share)	€ 0.34
BSPCE 2021-3 | Tranche four
Disclosure of detailed information of operating income loss [line items]
Price of underlying share (euro per share)	€ 0.35
BSPCE 2021-3 | Minimum
Disclosure of detailed information of operating income loss [line items]
Volatility	79.89%
Risk-free rate	2.8517%
BSPCE 2021-3 | Maximum
Disclosure of detailed information of operating income loss [line items]
Volatility	88.22%
Risk-free rate	3.0093%
BSPCE 2021-4
Disclosure of detailed information of operating income loss [line items]
Number of options granted (in shares) | shares	62,325
Exercise price (in euro per share)	€ 1.89
Price of underlying share (euro per share)	€ 0.37
Expected dividends	0%
Fair value of the plan (in K€) | €	€ 23,060
BSPCE 2021-4 | Minimum
Disclosure of detailed information of operating income loss [line items]
Volatility	80.52%
Risk-free rate	2.8625%
BSPCE 2021-4 | Maximum
Disclosure of detailed information of operating income loss [line items]
Volatility	88.06%
Risk-free rate	2.9676%
AGA 2022
Disclosure of detailed information of operating income loss [line items]
Number of options granted (in shares) | shares	16,460
Price of underlying share (euro per share)	€ 0.82
Expected dividends	0%
Fair value of the plan (in K€) | €	€ 135

NOTES RELATED_TO THE UNAUDITE_8

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) - Breakdown of Expenses of Plans per Financial Year (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	€ 391	€ 326
Employees
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	99	84
Executive officers and executive committee
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	183	242
Board members
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	109
AGA
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	66	202
AGA | Employees
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)		31
AGA | Executive officers and executive committee
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	66	171
BSA
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	435
BSA | Employees
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	222
BSA | Executive officers and executive committee
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	104
BSA | Board members
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	109
SO
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	(110)	124
SO | Employees
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	(123)	53
SO | Executive officers and executive committee
Disclosure Of Fair Value Of Equity Instruments Granted [Line Items]
Sharebased compensation expense recognized in profit (loss)	€ 13	€ 71

NOTES RELATED_TO THE UNAUDITE_9

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) - Summary of Financial Income and Expense (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Detailed Information Of Operating Income Loss [Abstract]
Income from short term deposits	€ 171	€ 6
Change in fair value of derivative liabilities	0	0
Foreign exchange gains	137	3,348
Other financial income	23	16
Financial income	331	3,370
Amortized cost of convertible notes	0	(22)
Financial expenses on lease liability	(25)	(108)
Interest expense related to borrowings	(78)	(140)
Foreign exchange loss	(239)	(480)
Other financial expenses	0	0
Financial expenses	(342)	(750)
Financial income (loss)	€ (11)	€ 2,620

NOTES RELATED_TO THE UNAUDIT_10

NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) - Summary of Basic Earnings per Share and Diluted Earnings (Loss) per Share (Details) - EUR (€) € / shares in Units, € in Thousands		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Detailed Information Of Operating Income Loss [Abstract]
Net loss (in thousands of euros)		€ (12,201)	€ (1,024)
Weighted number of shares for the period (in shares)		3,284,500	3,101,605
Basic loss per share (€/share)	[1]	€ (3.71)	€ (0.33)
Diluted loss per share (€/share)	[1]	€ (3.71)	€ (0.33)
Number of treasury shares held (in shares)		250
[1]Following PHAXIAM reverse share split by exchange of ten existing share for one new share on September 18th 2023, the Basic /Diluted loss per share has been restated retrospectively for all periods presented.

NOTES RELATED TO THE CONSOLID_3

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Schedule of Other Intangible Assets (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)
Disclosure of detailed information about intangible assets [line items]
Beginning balance	€ 5
Ending balance	17,101
IP R&D and Other intangible assets
Disclosure of detailed information about intangible assets [line items]
Beginning balance	5
Ending balance	17,101
IP R&D and Other intangible assets | GROSS VALUE
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,668
Business combination	17,098
Increase	0
Decrease	0
FX rate impact	0
Reclassification	0
Ending balance	18,766
IP R&D and Other intangible assets | ACCUMULATED AMORTIZATION AND IMPAIRMENT
Disclosure of detailed information about intangible assets [line items]
Beginning balance	(1,663)
Increase	(2)
Decrease	0
FX rate impact	0
Ending balance	€ (1,665)

NOTES RELATED TO THE CONSOLID_4

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Additional Information (Details) € / shares in Units, € in Thousands, $ in Thousands			1 Months Ended		6 Months Ended
	Jun. 23, 2023 EUR (€) installment € / shares	Jun. 24, 2020	Jun. 30, 2023 EUR (€) € / shares shares	May 31, 2023 shares	Jun. 30, 2023 EUR (€) € / shares shares	Jun. 30, 2022 EUR (€)	Sep. 18, 2023 shares	Jul. 27, 2023 € / shares	Jul. 26, 2023 € / shares	May 15, 2023 EUR (€) € / shares	Dec. 31, 2022 EUR (€)	Apr. 22, 2022 EUR (€)	Apr. 22, 2022 USD ($)
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Merger costs	€ 3,413				€ 3,410
Right of use			€ 2,943		2,943						€ 2,584
Research tax credit			2,603		2,603	€ 1,484
Term deposits			€ 12,084		€ 12,084						12,113
Maturity			1 month		1 month
Number of shares fully paid up (in shares) | shares			6,075,105		6,075,105
Number of shares fully paid up before share split (in shares) | shares			60,751,053		60,751,053
Nominal value (in euro per share) | € / shares			€ 1		€ 1
Number of ordinary shares issued (in shares) | shares			26,630,756	3,101,745
Maximum period, tranches		24 months
Note warrants outstanding (in shares) | shares			303,030		303,030
Conditional advances			€ 603		€ 603
Grant			€ 29		€ 29
Borrowings, maturity					7 years
Interest rate			2.25%		2.25%
Trade and other payables			€ 9,121		€ 9,121						5,115
Social liabilities, taxation and social security			3,554		3,554						2,799
Deferred revenue			420		420						51
Property, plant and equipment			857		857						393
Other financial income					23	16
Unsecured bank loans received			300		300
Financial liabilities – current portion			3,201		3,201						2,565
Financial liabilities – non-current portion			8,552		8,552						7,547
Research Tax Credit, Prior Year Carryforward
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Research tax credit						1,484
CIR Estimate
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Research tax credit			243		243
Reverse Stock Split
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Nominal value (in euro per share) | € / shares								€ 1	€ 0.10
Note warrants outstanding (in shares) | shares							30,303
Pherecydes
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Business combination					17,070
Percentage of voting equity interests acquired	100%
Loss of combined entity as if combination occurred at beginning of period					17,900
Number of installments | installment	2
Share price (in euro per share) | € / shares	€ 0.82									€ 0.95
Trade and other payables			3,300		3,300
Social liabilities, taxation and social security			1,339		1,339
Deferred revenue			416		416
Equity interests of acquirer	€ 21,686		€ 24,642		24,642					€ 2,956
Pherecydes | IP Osteoarticular Infection on Prostheses
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Business combination					14,404
Pherecydes | IP Endocarditis
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Business combination					2,666
Pherecydes | CIR Estimate
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Research tax credit						€ 876
Pherecydes
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Change in scope of consolidation					€ 2,000
Borrowings, maturity					5 years
Interest rate			2.25%		2.25%
Phagosclin
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Conditional advances			€ 345		€ 345
Phagogram
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Conditional advances			118		118
E. Coli
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Conditional advances			169		169
Bioserra Building
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Right of use			2,433		2,433
Nantes Premises | Pherecydes
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Right of use	64
Roussel Premises | Pherecydes
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Right of use	141
Research Equipment | Pherecydes
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Right of use	€ 205
Term deposits
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Term deposits			12,000		12,000						12,000
Convertible to cash
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Term deposits			100		100
Cell Therapy Manufacturing Facility
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Property, plant and equipment												€ 15,673	$ 17,146
Accumulated depreciation, amortisation and impairment
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Right of use			(4,416)		(4,416)						(4,280)
Property, plant and equipment			(6,299)		(6,299)						(6,383)
Impairment					0
Gross carrying amount
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Right of use			7,359		7,359						6,864
Property, plant and equipment			€ 7,155		€ 7,155						€ 6,775

NOTES RELATED TO THE CONSOLID_5

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Business Acquisition Consideration Transferred and Equity Instruments Issued (Details) - Pherecydes € / shares in Units, € in Thousands	Jun. 30, 2023 EUR (€) shares	Jun. 23, 2023 EUR (€) shares € / shares	May 15, 2023 EUR (€) shares € / shares
Disclosure of detailed information about business combination [line items]
Equity interests of acquirer	€ 24,642	€ 21,686	€ 2,956
Replacement Share-based Payment Awards	436
Consideration transferred (acquisition price)	€ 25,078	€ 25,078
Number of shares | shares	29,677,639	26,575,894	3,101,745
Share price (in euro per share) | € / shares		€ 0.82	€ 0.95

NOTES RELATED TO THE CONSOLID_6

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Fair Value of Identifiable Assets and Liabilities at Transaction (Details) - Pherecydes - EUR (€) € in Thousands	Jun. 30, 2023	Jun. 23, 2023
Disclosure of detailed information about business combination [line items]
Intangible assets	€ 17,098
Property, plant and equipment	485
Rights of use	478
Other non-current assets	83
Other current assets	1,925
Cash and cash equivalents	30
Financial liabilities	(2,936)
Lease obligations	(456)
Other non-current liabilities	(49)
Other current liabilities	(5,085)
Net assets acquired	€ 11,575	€ 11,575

NOTES RELATED TO THE CONSOLID_7

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Goodwill from Business Combination (Details) - Pherecydes - EUR (€) € in Thousands	Jun. 30, 2023	Jun. 23, 2023
Disclosure of detailed information about business combination [line items]
Consideration transferred (acquisition price)	€ 25,078	€ 25,078
Net assets acquired	€ (11,575)	(11,575)
Goodwill		€ 13,503

NOTES RELATED TO THE CONSOLID_8

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Schedule of Property, Plant and Equipment (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	€ 393
Ending balance	857
General equipment, fixtures and fittings
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	213
Ending balance	543
Plant, equipment and tooling
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	154
Ending balance	267
Office equipment and computers
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	25
Ending balance	44
Assets under construction
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0
Ending balance	0
GROSS VALUE
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	6,775
Business combination	485
Increase	53
Decrease	(155)
FX rate impact	(5)
Reclassification	0
Ending balance	7,155
GROSS VALUE | General equipment, fixtures and fittings
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	2,914
Business combination	346
Increase	0
Decrease	(155)
FX rate impact	(2)
Reclassification	0
Ending balance	3,103
GROSS VALUE | Plant, equipment and tooling
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	3,111
Business combination	110
Increase	53
Decrease	0
FX rate impact	(2)
Reclassification	0
Ending balance	3,272
GROSS VALUE | Office equipment and computers
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	750
Business combination	29
Increase	0
Decrease	0
FX rate impact	(1)
Reclassification	0
Ending balance	778
GROSS VALUE | Assets under construction
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0
Business combination	0
Increase	0
Decrease	0
FX rate impact	0
Reclassification	0
Ending balance	0
ACCUMULATED DEPRECIATION AND IMPAIRMENT
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(6,383)
Decrease	155
Depreciation	(74)
Impairment	0
FX rate impact	3
Reclassification	0
Ending balance	(6,299)
ACCUMULATED DEPRECIATION AND IMPAIRMENT | General equipment, fixtures and fittings
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(2,701)
Decrease	155
Depreciation	(16)
Impairment	0
FX rate impact	2
Reclassification	0
Ending balance	(2,560)
ACCUMULATED DEPRECIATION AND IMPAIRMENT | Plant, equipment and tooling
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(2,957)
Decrease	0
Depreciation	(49)
Impairment	0
FX rate impact	1
Reclassification	0
Ending balance	(3,005)
ACCUMULATED DEPRECIATION AND IMPAIRMENT | Office equipment and computers
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(725)
Decrease	0
Depreciation	(9)
Impairment	0
FX rate impact	0
Reclassification	0
Ending balance	€ (734)

NOTES RELATED TO THE CONSOLID_9

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Schedule of Right of Use (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	€ 2,584
Ending balance	2,943
GROSS VALUE
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	6,864
Business combination	478
Increase	17
Decrease	0
FX rate impact	0
Reclassification	0
Ending balance	7,359
ACCUMULATED DEPRECIATION AND IMPAIRMENT
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	(4,280)
Increase	(223)
Decrease	87
FX rate impact	0
Reclassification	0
Ending balance	(4,416)
Buildings
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	2,557
Ending balance	2,639
Buildings | GROSS VALUE
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	5,673
Business combination	205
Increase
Decrease
FX rate impact
Reclassification
Ending balance	5,878
Buildings | ACCUMULATED DEPRECIATION AND IMPAIRMENT
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	(3,116)
Increase	(210)
Decrease	87
FX rate impact	0
Reclassification	0
Ending balance	(3,239)
Plant, equipment and tooling
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	0
Ending balance	273
Plant, equipment and tooling | GROSS VALUE
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	954
Business combination	273
Increase
Decrease
FX rate impact
Reclassification
Ending balance	1,227
Plant, equipment and tooling | ACCUMULATED DEPRECIATION AND IMPAIRMENT
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	(954)
Increase
Decrease	0
FX rate impact	0
Reclassification	0
Ending balance	(954)
Transport equipment
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	27
Ending balance	31
Transport equipment | GROSS VALUE
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	119
Business combination
Increase	17
Decrease
FX rate impact
Reclassification
Ending balance	136
Transport equipment | ACCUMULATED DEPRECIATION AND IMPAIRMENT
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	(92)
Increase	(13)
Decrease	0
FX rate impact	0
Reclassification	0
Ending balance	(105)
Office equipment and computers
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	0
Ending balance	0
Office equipment and computers | GROSS VALUE
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	118
Business combination
Increase
Decrease
FX rate impact
Reclassification
Ending balance	118
Office equipment and computers | ACCUMULATED DEPRECIATION AND IMPAIRMENT
Disclosure Of Detailed Information Of Right Of Use [Line Items]
Beginning balance	(118)
Increase
Decrease	0
FX rate impact	0
Reclassification	0
Ending balance	€ (118)

NOTES RELATED TO THE CONSOLI_10

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Schedule of Trade Receivables and Other Current Assets (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Notes Related To The Consolidated Statements Of Financial Position [Abstract]
Trade and other receivables	€ 245	€ 76	€ 76
Research Tax Credit	2,603		1,484
Other receivables (including tax and social receivables)	1,251		973
Net investment in a sublease	0		43
Deposits related to leased premises	(40)		121
Advance payments and deposits to suppliers	342		342
Prepaid expenses	1,331		805
Total other current assets	€ 5,488	€ 3,769	€ 3,769	€ 5,488

NOTES RELATED TO THE CONSOLI_11

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Notes Related To The Consolidated Statements Of Financial Position [Abstract]
Current account	€ 13,105	€ 26,676
Term deposits	12,084	12,113
Total cash and cash equivalents as reported in statement of financial position	25,189	38,789
Bank overdrafts	0	0
Total cash and cash equivalents as reported in statement of cash flow	€ 25,189	€ 38,789	€ 53,339	€ 33,699

NOTES RELATED TO THE CONSOLI_12

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Financial Liabilities by Type (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	€ 10,112
Business combination	2,916
Increase	12
Fair value of embedded derivatives	0
Amortized cost	0
Conversion	0
Extinguishment of conditional advance	0
Repayment	(1,282)	€ 0
FX rate impact	(3)
Liabilities arising from financing activities at end of period	11,753
Convertible notes
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	0
Business combination	0
Increase	0
Fair value of embedded derivatives
Amortized cost
Conversion
Extinguishment of conditional advance
Repayment	0
FX rate impact
Liabilities arising from financing activities at end of period	0
Conditional advances
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	0
Business combination	603
Increase	0
Fair value of embedded derivatives
Amortized cost
Conversion
Extinguishment of conditional advance
Repayment	0
FX rate impact
Liabilities arising from financing activities at end of period	603
Bank loans
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	10,071
Business combination	2,313
Increase	12
Fair value of embedded derivatives
Amortized cost
Conversion
Extinguishment of conditional advance
Repayment	(1,243)
FX rate impact
Liabilities arising from financing activities at end of period	11,153
Other
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Liabilities arising from financing activities at beginning of period	41
Business combination
Increase	0
Fair value of embedded derivatives
Amortized cost
Conversion
Extinguishment of conditional advance
Repayment	(39)
FX rate impact	(3)
Liabilities arising from financing activities at end of period	€ (1)

NOTES RELATED TO THE CONSOLI_13

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Financial Liabilities by Maturity (Details) € in Thousands	Jun. 30, 2023 EUR (€)
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Convertible notes	€ 0
Conditional advances	603
Bank loans	11,151
Other	1
Total financial liabilities	11,753
Less than one year
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Convertible notes	0
Conditional advances	121
Bank loans	3,198
Other	1
Total financial liabilities	3,321
One to three years
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Convertible notes	0
Conditional advances	481
Bank loans	6,784
Other	0
Total financial liabilities	7,265
Three to five years
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Convertible notes	0
Conditional advances	0
Bank loans	1,169
Other	0
Total financial liabilities	1,169
More than five years
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Convertible notes	0
Conditional advances	0
Bank loans	0
Other	0
Total financial liabilities	€ 0

NOTES RELATED TO THE CONSOLI_14

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Lease Liabilities (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Lease liabilities, beginning balance	€ 3,455
Increase without cash impact	17
Repayment	(414)	€ (907)
Decrease without cash impact	(127)
FX rate impact	(1)
Capitalized interests	0
Reclassification	0
Lease liabilities, ending balance	3,387
Pherecydes
Notes Related To The Consolidated Statements Of Financial Position [Line Items]
Lease obligations	€ (456)

NOTES RELATED TO THE CONSOLI_15

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Lease Liabilities By Maturity (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	€ 3,387	€ 3,455
Less than one year
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	828
One to three years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	1,255
Three to five years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	1,303
More than five years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Lease liabilities	€ 0

NOTES RELATED TO THE CONSOLI_16

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Trade Payables and Other Current Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Notes Related To The Consolidated Statements Of Financial Position [Abstract]
Vendors	€ 4,336	€ 1,562
Vendors - accruals	4,785	3,553
Total trade and other payables	9,121	5,115
Social liabilities, taxation and social security	3,554	2,799
Fixed assets payables	0	0
Deferred revenue	420	51
Other payables	59	59
Total other current liabilities	€ 4,033	€ 2,909

NOTES RELATED TO THE CONSOLI_17

NOTES RELATED TO THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - Summary of Financial Instruments Recognized in the Consolidated Statement of Financial Position and Effect on Net Income (Loss) (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [line items]
Trade and other receivables	€ 245	€ 76	€ 76
Other current assets	5,488	3,769	€ 3,769	€ 5,488
Cash and cash equivalents	25,189	38,789
Financial liabilities – non-current portion	8,552	7,547
Lease liabilities - non-current portion	2,559	2,680
Financial liabilities – current portion	3,201	2,565
Lease liabilities - current portion	828	775
Trade and other payables	9,121	5,115
Other current liabilities	4,033	2,909
Total financial liabilities	11,753
Pherecydes
Disclosure of detailed information about financial instruments [line items]
Trade and other payables	3,300
Financial liabilities at carrying value
Disclosure of detailed information about financial instruments [line items]
Financial liabilities – non-current portion		7,547
Lease liabilities - non-current portion		2,680
Financial liabilities – current portion		2,565
Lease liabilities - current portion		775
Trade and other payables		5,115
Other current liabilities		2,858
Total financial liabilities		21,540
Financial liabilities at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities		0
Financial liabilities at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Financial liabilities – non-current portion	8,552	7,547
Lease liabilities - non-current portion	2,559	2,680
Financial liabilities – current portion	3,201	2,565
Lease liabilities - current portion	828	775
Trade and other payables	9,120	5,115
Other current liabilities	3,613	2,858
Total financial liabilities	27,873	21,540
Financial liabilities at fair value, class
Disclosure of detailed information about financial instruments [line items]
Financial liabilities – non-current portion	8,552	7,547
Lease liabilities - non-current portion	2,559	2,680
Financial liabilities – current portion	3,201	2,565
Lease liabilities - current portion	828	775
Trade and other payables	9,120	5,115
Other current liabilities	3,613	2,858
Total financial liabilities	27,873	21,540
Financial assets at carrying value
Disclosure of detailed information about financial instruments [line items]
Financial liabilities – non-current portion	8,552
Lease liabilities - non-current portion	2,559
Financial liabilities – current portion	3,201
Lease liabilities - current portion	828
Trade and other payables	9,120
Other current liabilities	3,613
Total financial liabilities	27,873
Financial assets at carrying value
Disclosure of detailed information about financial instruments [line items]
Other non-current financial assets	205	195
Other current financial assets	302	464
Trade and other receivables	245	76
Other current assets	3,854	1,798
Cash and cash equivalents	25,189	38,789
Total financial assets	29,795	41,322
Financial assets at fair value through profit or loss, category
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	25,189	38,789
Total financial assets	25,189	38,789
Financial assets at amortised cost, category
Disclosure of detailed information about financial instruments [line items]
Other non-current financial assets	205	195
Other current financial assets	302	464
Trade and other receivables	245	76
Other current assets	3,854	1,798
Total financial assets	4,606	2,533
Financial assets at fair value
Disclosure of detailed information about financial instruments [line items]
Other non-current financial assets	205	195
Other current financial assets	302	464
Trade and other receivables	245	76
Other current assets	3,854	1,798
Cash and cash equivalents	25,189	38,789
Total financial assets	€ 29,795	€ 41,322

RELATED PARTIES - Summary of Re

RELATED PARTIES - Summary of Remuneration of Directors and Members of the Executive Committee (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of transactions between related parties [line items]
Salary / fees	€ 1,399	€ 1,816
Retirement benefits	19	171
Share based payments	(33)	242
Executive officers / VP and qualified person
Disclosure of transactions between related parties [line items]
Salary / fees	875	630
Retirement benefits	11	110
Share based payments	136	222
Executive committee
Disclosure of transactions between related parties [line items]
Salary / fees	368	993
Retirement benefits	8	61
Share based payments	(169)	20
Board of directors
Disclosure of transactions between related parties [line items]
Salary / fees	156	193
Retirement benefits	0
Share based payments	€ 0

RELATED PARTIES - Additional In

RELATED PARTIES - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 manager	Jun. 23, 2023
Disclosure of transactions between related parties [line items]
Number of deputy general manager	2
Chief Executive Officer
Disclosure of transactions between related parties [line items]
Health insurance contribution maximum		0.60
Employee benefits contribution maximum		0.60
Supplemental retirement contribution maximum		0.50
Chief Executive Officer and Deputy General Managers
Disclosure of transactions between related parties [line items]
Compensation, remuneration period	12 months
Chief Executive Officer and Deputy General Managers | Maximum
Disclosure of transactions between related parties [line items]
Compensation, remuneration period	18 months

OFF-BALANCE SHEET COMMITMENTS -

OFF-BALANCE SHEET COMMITMENTS - Additional Information (Details) € in Millions, $ in Millions		12 Months Ended		24 Months Ended
	Jun. 24, 2020	Dec. 31, 2019 USD ($)	Dec. 31, 2019 EUR (€)	Jun. 30, 2021 lease	Jun. 24, 2019 USD ($)
Disclosure Of Off Balance Sheet Commitments [Line Items]
Maximum period, tranches	24 months
Number of sublease agreements | lease				2
SQZ Biotechnologies
Disclosure Of Off Balance Sheet Commitments [Line Items]
Upfront payment received		$ 1	€ 0.9
SQZ Biotechnologies | Top of range
Disclosure Of Off Balance Sheet Commitments [Line Items]
Potential development, regulatory and commercial mile stone payments | $					$ 56